Regulatory Heamatoindices

Vol 1

ISBN : 978-93-340-7137-5

Authors

Dr. Titlee Majumder
Dr. Rajen Dey
Mr. Manojit Bysack
Ms. Oly Banerjee
Mr. Rupak Bera

REGULATORY HEMATOINDICES

Volume 1

AUTHORS:

DR. TITLEE MAJUMDER

DR. RAJEN DEY

MR. MANOJIT BYSACK

MS. OLY BANERJEE

MR. RUPAK BERA

SWAMI VIVEKANANDA UNIVERSITY

Published by Swami Vivekananda University (Institutional Publishers), Kolkata-700121

Swami Vivekananda University (Institutional Publisher),

Kolkata-700121, India.

ISBN: First Edition: August, 2023

Publisher: Swami Vivekananda University (Institutional Publisher), Kolkata-700121, India
Contact us: hod.mlt@svu.ac.in

Preface

The book entitled is a comprehensive overview which is an amalgamation of "REGULATORY-HEMATOINDICES", traditional aspects of hematology and other blood borne disease with recent dimensions of those same. The futuristic approaches relating conventional and newer frontiers are now considered as the most dominant vision for research. This field relates every part of the medical sciences like: physiology, pathophysiology, psychological health management, diagnostics and instruments followed by every even and odds.

The chapters given in the book are based upon the classical concepts of diseases based of parametric of blood cells as well as some new ventured domains of it has been uncovered. The first volume of the book offers a comprehensive exploration into the intricate relationship between hematological disorders and its illustrative modes of therapeutic management shedding light on the fascinating interplay between these seemingly disparate medical fields

This book serves as a valuable resource offering a nuanced and integrated perspective that enriches clinical decision-making fosters interdisciplinary collaborations and stimulates further research endeavors

It aspires to be a cornerstone reference in the ever-evolving landscape of medical literature bridging gaps and fostering a holistic approach towards patient care

This book is a culmination of collaborative efforts by leading experts in haematological disorders and its treatment and management aiming to provide a holistic understanding of how these domains intersect and influence each other

This will further help students to delve into the fundamental principles of blood physiology and the mechanisms by which infectious agents invade the body

Different chapters in this book explore how infections influence hematological processes and how hematological as well as serological conditions might predispose individuals to

infections which will further uncover the complex interdependencies and feedback loops between these two domains

This book examines the diverse clinical presentations resulting from the interaction between hematological disorders and therapeutic indices and help students learn about the sophisticated diagnostic tools and approaches used to discern and manage these intertwined conditions.

This book highlights the challenges and nuances in treating patients affected by concurrent hematological and therapeutic indices along with its regulatory conditions along with management including novel drug therapies and tailored approaches addressing both aspects simultaneously

Lastly it investigates the latest advancements and on-going research frontiers in both haematological disorder and its management shows promising avenues that hold potential for transforming clinical practice and patient care.

Thank you for embarking on this journey with us, and we hope you find this book both informative and inspiring.

(Dr. Titlee Majumder)

Assistant Professor, Swami Vivekananda University,Kolkata, West Bengal, India

Acknowledgement

I am writing to show my sincere gratitude for the support and encouragement to Swami Vivekananda University, Kolkata, India provided in the creation of this book, **"Regulatory Hematoindices, Volume 1".** The commitment from university to fostering education and research has played a pivotal role in shaping the content and direction of this publication. We are extremely thankful of the collaborative spirit and resources offered by Swami Vivekananda University, Kolkata which have allowed us to exploreand share the latest innovations and technologies across various fields. We hope that this book serves as a valuable resource for this esteemed institution and the broader academic community, reflecting our shared dedication to knowledge, progress, and the pursuit of excellence.

With sincere appreciation,

Thank you

Dr. Titlee Majumder

Assistant Professor, Swami Vivekananda University

Barrackpore, Kolkata, West Bengal, India

700121

Authors' conflict

We state to declare that no authors have shown any misjudgment and confliction of decisions during the time of preparing contents of book & no such data have been manipulated of falsified during writing.

The traditional concept of hematological disorders has been catered and the cytological alteration in the volume of the blood is the primary area of emitting knowledge, which is a cumulative decision of the authors.

Thank you

Dr. Titlee Majumder

Assistant Professor, Swami Vivekananda University

Barrackpore, Kolkata, West Bengal, India

700121

List of Authors

1. Dr. Titlee Majumder, Assistant Professor & Head, Department of Medical Laboratory Technology, Swami Vivekananda University.
2. Dr. Rajen Dey, Assistant Professor, Department of Medical Laboratory Technology, Swami Vivekananda University.
3. Mr. Manojit Bysack, Assistant Professor, Department of Medical Laboratory Technology, Swami Vivekananda University.
4. Ms. Oly Banerjee, Assistant Professor, Department of Medical Laboratory Technology, Swami Vivekananda University.
5. Mr. Rupak Bera, Laboratory Assistant, Department of Medical Laboratory Technology, Swami Vivekananda University.
6. Mr. Arghya Naskar, Student Semester V, Department of Medical Laboratory Technology, Swami Vivekananda University.

Table of Contents:

Chapter 1

A COMPREHENSIVE EXAMINATION OF ANEMIA: CLASSIFICATIONS, ORIGINS, INDICATIONS, AND THERAPEUTIC APPROACHES

Chapter 2

ACUTE MYELOID LEUKAEMIA-TYPES AND TREATMENT STRATEGIES

Chapter 3

An In-Depth Analysis of Thalassemia: Causes, Diagnosis & Management

Chapter 4

AN IN-DEPTH INVESTIGATION OF RISK FACTORS ASSOCIATED WITH SEPSIS AND THE POTENTIAL TREATMENT MODALITY

Chapter 5

PURPURA FULMINANS: A HEMORRHAGIC INFARCTION

Chapter 1

A COMPREHENSIVE EXAMINATION OF ANEMIA: CLASSIFICATIONS, ORIGINS, INDICATIONS, AND THERAPEUTIC APPROACHES

Ms. Oly Banerjee

Email: olyb@svu.ac.in

Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal-700121, India

Overview

Anemia represents a prevalent nutritional deficiency disorder and a significant global public health concern, impacting both developing and developed nations, with profound implications for human health and socio-economic progress (WHO, 2005). As per reports from the World Health Organization (WHO) in 2004, approximately one third of the global population, exceeding 2 billion individuals, suffers from anemia due to imbalances in their dietary intake (WHO, 2004). Hence, this review aims to explore various aspects of anemia, including its types, causes, symptoms, and available treatments.

1. Introduction

Anemia, a prevalent nutritional deficiency disorder and a significant global public health concern, affects populations in both developing and developed countries, with far-reaching implications for human health and socio-economic development (WHO, 2005). According to reports from the World Health Organization (WHO) in 2004, over two billion people, constituting approximately one third of the global population, suffer from anemia due to imbalances in their dietary intake.

Of particular concern is the situation in South Asian countries, where India stands out with the highest prevalence of anemia (WHO). Alarmingly, about half of the global maternal deaths attributable to anemia occur in South Asian nations, with India accounting for approximately 80 percent of these maternal deaths (Ezzati et al., 2002).



Age-standardized point prevalence of anemia per 100,000 population in 2019, by country. (Generated from data available from http://ghdx.healthdata.org/gbd-results-tool) (Adopted from Safiri et al., 2021)

1.2. Classification of Anemia

Anemia encompasses several classifications and types, each stemming from various defects in red blood cells. These defects may include issues with red cell production (such as aplastic anemia), maturation (like megaloblastic anemia), hemoglobin synthesis (as seen in iron deficiency anemia), genetic anomalies affecting hemoglobin maturation (thalassemia), or the synthesis of abnormal hemoglobin (hemoglobinopathies, sickle cell anemia, and certain types of thalassemia). Additionally, physical loss of red cells (hemolytic anemias) can contribute to the development of anemia (Mukherjee and Ghosh, 2012). Anemia is characterized by a deficiency of red blood cells in the body, resulting in an inability to meet the organism's oxygen demands. Understanding the various classifications of anemia can aid in recognizing symptoms and implementing preventive measures to mitigate its occurrence.

1.2.1 Iron-Deficiency Anemia

Iron plays a crucial role in various bodily functions, particularly in the synthesis of hemoglobin. The diagram below illustrates the distribution and storage of iron (Fe) in different parts of the human body. Iron-deficiency anemia occurs when there is an insufficient amount of iron present in the bloodstream. This type of anemia is more prevalent among adolescents and premenopausal women. Contributing factors include blood loss from heavy menstrual periods, internal bleeding in the gastrointestinal tract, or excessive blood donation. A deficiency in iron levels leading to anemia can arise from various causes, including pregnancy or childhood growth spurts, poor absorption of iron, gastrointestinal bleeding, dietary deficiencies (such as an iron-poor or restricted diet), certain medications (such as aspirin, ibuprofen, naproxen, and diclofenac), inadequate intake of specific vitamins (like folic acid and vitamin B12), kidney bleeding, hookworm infection, red blood cell disorders, and bone marrow disorders (Harper et al., 2015).



Indices for assessing iron status at various stages of iron-deficiency anemia.

(Adopted from Sundararajan and Rabe et al., 2021)

Symptoms

Iron-deficiency anemia can manifest through various symptoms, including fatigue, lethargy, dizziness, easy breathlessness, headaches, irregular heartbeats (palpitations), changes in taste perception, mouth soreness, and ringing in the ears (tinnitus). During pregnancy, anemia heightens the risk of complications for both the mother and baby, such as low birth weight,

premature delivery, and postnatal depression. Additionally, inadequate iron reserves in the newborn can result in anemia shortly after birth (Pasricha et al., 2010).

1.2.3 Pernicious Anemia

Pernicious anemia stands as the leading cause of Vitamin B12 deficiency, a vital nutrient crucial for sustaining life. Vitamin B12 plays a pivotal role in the generation of new cells in the body, including the constant production of red blood cells. Dietary sources of Vitamin B12 include meat, fish, eggs, and dairy products. Insufficient intake of Vitamin B12 results in anemia and may lead to other health complications. Pernicious anemia typically develops in individuals over the age of 50, with a higher prevalence among women compared to men, often exhibiting familial patterns. Additionally, it is more prevalent among individuals with other autoimmune disorders. Certain medications can also interfere with the absorption of Vitamin B12, notably metformin, colchicine, neomycin, and specific anticonvulsants utilized in the treatment of epilepsy (Turner and Talbot, 2009).

Symptoms

Pernicious anemia, stemming from Vitamin B12 deficiency, can manifest a range of psychological and nervous system symptoms. These may include depression, confusion, memory difficulties, and in severe cases, dementia. Nervous system manifestations can include sensations of numbness, tingling (pins and needles), changes in vision, and unsteadiness. Prolonged or severe Vitamin B12 deficiency can lead to permanent damage to the brain or nerves, underscoring the importance of timely diagnosis and treatment (Turner and Talbot, 2009).

1.2.4 Haemolytic Anaemia

Haemolytic anaemia describes a condition in which red blood cells are prematurely destroyed and eliminated from the bloodstream before completing their normal lifespan. This disorder can affect individuals of all ages, ethnicities, and genders. Haemolytic anaemia can result in various health complications, including fatigue, pain, irregular heart rhythms, cardiac enlargement, and heart failure. Inherited forms of haemolytic anaemia encompass conditions such as sickle cell anaemia, thalassaemias, hereditary spherocytosis, hereditary elliptocytosis, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and pyruvate kinase deficiency. Acquired forms of haemolytic anaemia include immune-mediated, autoimmune, alloimmune, drug-induced, and mechanical causes. Additionally, certain infections and substances have

the potential to damage red blood cells and trigger haemolytic anaemia. Examples include paroxysmal nocturnal haemoglobinuria and specific infections or toxins.

Symptoms

Fatigue stands out as the most prevalent symptom of anemia. A diminished red blood cell count can also result in shortness of breath, dizziness, headaches, coldness in the extremities (hands or feet), pale complexion, pale gums, and nail beds, as well as chest pain. Symptoms specific to haemolytic anaemia encompass jaundice, pain in the upper abdomen, leg ulcers and pain, and severe reactions to blood transfusions.

Treatment approaches for haemolytic anaemia include blood transfusions, medication, plasmapheresis, surgical interventions, blood and marrow stem cell transplants, and lifestyle modifications (Natasha and Yasmin, 2010).

1.2.5 Sickle Cell Anemia

Sickle cell anemia is a type of anemia characterized by the production of sickle-shaped ("C"-shaped) red blood cells. These cells contain abnormal hemoglobin, resulting in their distinctive sickle shape and reduced ability to move smoothly through blood vessels. Clusters of sickle cells can obstruct blood flow to various limbs and organs, leading to episodes of pain, severe infections, and organ damage. Sickle cells typically have a shorter lifespan of about 10 to 20 days, and the body cannot replenish red blood cells quickly enough to compensate for their rapid destruction, resulting in anemia.

Symptoms

Sickle cell anemia is a hereditary condition that persists throughout a person's life, and it is most prevalent in regions such as Africa, South or Central America, the Caribbean islands, Mediterranean countries, India, and Saudi Arabia. Common symptoms of sickle cell anemia include fatigue, shortness of breath, dizziness, headaches, coldness in the hands and feet, pale skin, and chest pain.

1.2.6 Thalassaemia

It is an inherited blood disorder characterized by a reduced production of healthy red blood cells and diminished levels of hemoglobin. The condition manifests in two primary forms: alpha- and beta-thalassaemia. The most severe variant of alpha thalassaemia is referred to as

alpha thalassaemia major or hydrops fetalis, while the severe form of beta thalassaemia is known as thalassaemia major or Cooley's anaemia. Thalassaemias can affect individuals of both sexes and are most prevalent among people of Italian, Greek, Middle Eastern, Asian, and African descent. Hemoglobin, a vital component of red blood cells, consists of two types of protein chains: alpha globin and beta globin. Insufficient production of these protein chains results in abnormal formation of red blood cells, leading to inadequate oxygen transport. Thalassaemias arise when the genes responsible for producing hemoglobin protein chains are either absent or mutated. The disorder is inherited from parents to their offspring through genetic transmission.

Symptoms

Symptoms of thalassaemias stem from a deficiency of oxygen in the bloodstream. The severity of these symptoms varies depending on the extent of the disorder. Individuals with alpha or beta thalassaemia may experience mild anaemia, while those with beta thalassaemia intermedia may present with mild to moderate anaemia. Additionally, they may encounter other health issues such as slowed growth, delayed puberty, bone problems, and an enlarged spleen. Individuals with severe forms of thalassaemia, such as haemoglobin H disease or beta thalassaemia major, exhibit more pronounced symptoms and serious health complications. These may include a pale and lethargic appearance, poor appetite, dark urine, slowed growth, delayed puberty, jaundice, enlarged spleen, liver, and heart, as well as bone problems. The treatment for moderate to severe forms of thalassaemia typically involves three main approaches: blood transfusions, iron chelation therapy to manage iron overload, and folic acid supplements to support red blood cell production.

1.2.7 Aplastic Anaemia

Aplastic anaemia is a blood disorder characterized by inadequate production of new blood cells in the body's bone marrow. This deficiency can lead to various health complications, including arrhythmias, cardiac enlargement, heart failure, infections, and bleeding. Damage to the stem cells within the bone marrow is the underlying cause of aplastic anaemia (Scheinberg and Young, 2012). Several acquired diseases, conditions, and factors can contribute to the development of aplastic anaemia, including exposure to toxins such as pesticides, arsenic, and benzene, as well as radiation and chemotherapy treatments. Certain medications like chloramphenicol, infectious diseases such as hepatitis, Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV, and autoimmune disorders like lupus and

rheumatoid arthritis can also trigger aplastic anaemia. Additionally, inherited conditions such as Fanconi anaemia, Shwachman-Diamond syndrome, dyskeratosis, and Diamond-Blackfan anaemia may lead to aplastic anaemia (Brodsky and Jones, 2005). The most common symptoms of aplastic anaemia include fatigue, shortness of breath, dizziness, headaches, cold extremities, pale skin, gums, and nail beds, as well as chest pains. Treatment for aplastic anaemia typically involves blood transfusions, blood and marrow stem cell transplants, and medication. These interventions aim to prevent or minimize complications, alleviate symptoms, and enhance quality of life. In some cases, blood and marrow stem cell transplants may offer a potential cure for the disorder.

1.3 Causes of Anaemia

A well-balanced diet typically provides sufficient iron to meet the body's requirements. However, inadequate dietary intake of iron, folic acid, and foods that enhance iron absorption, combined with poor iron bioavailability, constitute major contributing factors to the high prevalence of anaemia (Prema, 1989 & 1992). Poor iron reserves at birth (Kilbridge et al., 1999), low iron content in breast milk, and insufficient dietary iron intake during infancy and childhood contribute to the elevated prevalence of anaemia in childhood (Toteja and Singh, 2004; Kapur et al., 2002).

1.4 Nutritional Treatment of Anaemia

Treating anemia involves focusing on consuming foods that aid in hemoglobin synthesis, particularly those rich in iron, copper, zinc, folic acid, vitamin B12, and protein. The combination of iron and B-vitamins is especially beneficial for treating anemia.

1.4.1 Vitamin B12: Low levels of vitamin B12 can lead to pernicious anemia, which is often treated with vitamin B12 supplements. Food sources rich in vitamin B12 include breakfast cereals fortified with vitamin B12, meats such as beef, liver, poultry, and fish, eggs, dairy products like milk, yogurt, and cheese, and foods fortified with vitamin B12 such as soy-based beverages and vegetarian burgers.

1.4.2 Folic Acid: Folic acid, a form of vitamin B, is essential for making and maintaining new cells, including red blood cells. It is particularly crucial for pregnant women to prevent anemia and promote healthy fetal growth. Foods high in folic acid include bread, pasta, and rice fortified with folic acid, dark green leafy vegetables like spinach, black-eyed peas, dried beans, beef liver, eggs, bananas, oranges, and other fruits and juices.

1.4.3 Vitamin C: Vitamin C aids in the absorption of iron. Good sources of vitamin C include vegetables and fruits, especially citrus fruits like oranges, grapefruits, tangerines, kiwi fruit, strawberries, cantaloupes, broccoli, peppers, Brussels sprouts, tomatoes, cabbage, potatoes, and leafy green vegetables such as turnip greens and spinach. Fresh and frozen fruits, vegetables, and juices typically contain more vitamin C than canned varieties.

1.4.4 Foods to Eat for Anemia:

Anemia results from a deficiency in the quality and quantity of hemoglobin, which is vital for transporting oxygen from the lungs to the body's tissues. Consuming iron-rich fruits like apples and tomatoes can be beneficial for treating anemia. Other fruits effective in treating anemia include plums, bananas, lemons, grapes, raisins, oranges, figs, carrots, and raisins when consumed in large quantities. These fruits contribute to increasing iron intake and supporting hemoglobin synthesis, thereby alleviating symptoms associated with anemia such as fatigue, insomnia, dizziness, pale skin, shortness of breath, irregular menstrual cycles, and rapid heartbeat.

1.4.5 Honey: Honey is a rich source of iron, copper, and manganese, which play crucial roles in hemoglobin synthesis. When these elements are combined, they contribute to the production of hemoglobin, making honey a potent tool against anemia.

1.4.6 Meats: Red meats like kidney, heart, and liver are highly effective in treating anemia due to their high iron content. Poultry, fish, and oysters are also beneficial for combating anemia.

1.4.7 Vegetables: Iron-rich vegetables such as spinach, lettuce, beets, broccoli, fenugreek, celery, and kale are packed with nutrients essential for treating anemia. These vegetables not only provide iron but also supply vitamin B12 and folic acid, which are vital for energy production and healing from anemia. Beetroot juice, in particular, is nutritious tonic rich in iron, offering relief from fatigue and lethargy associated with anemia.

1.4.8 Legumes and Nuts: Legumes like pulses, almonds, whole grain cereals, dry dates, peanuts, and walnuts are effective in addressing the symptoms and causes of anemia, thanks to their nutrient-rich profiles.

1.5 Therapeutic Management of Anemia

Anemia is a condition characterized by a decrease in the number of red blood cells (RBCs) or hemoglobin, leading to reduced oxygen-carrying capacity of the blood. Therapeutic intervention or management of anemia depends on the underlying cause. Here are the general strategies for different types of anemia:

Iron-Deficiency Anemia

Cause: Lack of iron, often due to poor diet, chronic blood loss, or malabsorption.

Treatment:

- **Oral Iron Supplements:** Ferrous sulfate, ferrous gluconate, or ferrous fumarate.
- **Dietary Changes:** Increase intake of iron-rich foods (red meat, beans, lentils, fortified cereals, dark leafy greens).
- **Intravenous Iron:** For individuals who cannot tolerate oral iron or have severe deficiency.
- **Treating the Underlying Cause:** Address chronic blood loss sources, such as gastrointestinal bleeding or heavy menstrual periods.

Vitamin B12 Deficiency Anemia (Pernicious Anemia)

Cause: Lack of vitamin B12, often due to poor absorption, vegan diet, or pernicious anemia.

Treatment:

- **Vitamin B_{12} Injections:** For individuals with absorption issues (e.g., pernicious anemia).
- **Oral Vitamin B_{12} Supplements:** For those who can absorb B12 orally.
- **Dietary Changes:** Increase intake of B12-rich foods (meat, dairy products, eggs, fortified cereals).

Folate-Deficiency Anemia

Cause: Lack of folate (vitamin B9), often due to poor diet, malabsorption, or increased demand (e.g., pregnancy).

Treatment:

- **Oral Folate Supplements:** Folic acid tablets.
- **Dietary Changes:** Increase intake of folate-rich foods (leafy green vegetables, fruits, nuts, beans, peas).

Anemia of Chronic Disease

Cause: Chronic illnesses such as chronic kidney disease, cancer, rheumatoid arthritis, or infections.

Treatment:

- **Treat Underlying Condition:** Managing the chronic disease effectively.
- **Erythropoiesis-Stimulating Agents (ESAs):** For cases associated with chronic kidney disease.
- **Iron Supplements:** If iron deficiency is also present.

Hemolytic Anemia

Cause: Premature destruction of RBCs due to autoimmune disorders, infections, certain medications, or inherited conditions like sickle cell disease.

Treatment:

- **Immunosuppressive Drugs:** For autoimmune hemolytic anemia (e.g., corticosteroids).
- **Treat Infections:** If infection-induced.
- **Blood Transfusions:** In severe cases.
- **Sickle Cell Disease Management:** Hydroxyurea, blood transfusions, pain management, and possibly bone marrow transplant.

Aplastic Anemia

Cause: Bone marrow failure leading to reduced production of RBCs, WBCs, and platelets.

Treatment:

- **Immunosuppressive Therapy:** For autoimmune causes.
- **Bone Marrow Transplant:** Especially in younger patients.
- **Blood Transfusions:** To manage symptoms.
- **Growth Factors:** Such as erythropoietin or granulocyte colony-stimulating factor (G-CSF).

Thalassemia

Cause: Genetic disorder causing abnormal hemoglobin production.

Treatment:

- **Regular Blood Transfusions:** To maintain adequate hemoglobin levels.
- **Iron Chelation Therapy:** To prevent iron overload from transfusions.
- **Folic Acid Supplements:** To support RBC production.

- **Bone Marrow Transplant:** In severe cases.

General Management Tips

- **Regular Monitoring:** Regular blood tests to monitor hemoglobin levels and the effectiveness of treatment.
- **Patient Education:** Educating patients about dietary changes, medication adherence, and recognizing symptoms of anemia.
- **Addressing Symptoms:** Managing fatigue, weakness, and other symptoms through lifestyle modifications and supportive care.

Each type of anemia requires a tailored approach based on the specific etiology and patient factors. Collaboration between primary care physicians, hematologists, dietitians, and other specialists is often necessary to optimize treatment outcomes.

Conclusion: Anaemia poses a significant global health risk, particularly among teenagers and pregnant women. Early diagnosis and treatment are essential to ensure the health and well-being of future generations. By incorporating nutrient-rich foods like honey, meats, vegetables, legumes, and nuts into the diet, individuals can combat anemia and promote overall health.

References

Brodsky, R.A. and Jones, R.J., 2005. Aplastic anaemia. Lancet. 365(9471):1647-56.

Ezzati, M, Lopus, A.D., Dogers, A., Vander, H.S., Murray C., 2002. Selected major risk factors and global and regional burden of disease. Lancet 360 : 1347-60

Guidelines for the management of iron deficiency anaemia, British Society of Gastroenterology (March 2011)

Harper, J.L., Marcel, E.C. and Emmanuel, C. B., 2015. Iron Deficiency Anemia:Practice essentials, Pathophysiology and Etiology.Medscape.

http://www.health24.com/Medical/Anaemia/Anaemia-20130216-2, 20113

Kapur, D., Agarwal, K.N., Sharma, S., Kela, K., Kaur, I., 2002. Iron status of children aged 9-36 months in an urban slum Integrated Child Development Services project in Delhi. Indian Pediatr. 139:136-44.

Kilbridge, J., Bakea, T.G., Parapia, L.A., Khoury, S.A., Shugaidef, S.W., Jerwood, D., 1999. Anaemia during pregnancy as a risk factor for iron-deficiency anaemia in infancy: a case-control study in Jordan. Int. J. Epidemiol 28:461-8.

Ministry of Family and Health Welfare. 2002/2003. District-Level Household Survey. New Delhi, Government of India.

Mukherjee, K.L., Ghosh, S., 2012. Medical laboratory Technology. Procedure Manual for Routine Diagnostic Tests. Vol I (Second edition), 263-266.

Natasha, S., Yasmin G., 2010. Inkosi Albert Luthuli Central Hospital. Proceedings of South African Thalassaemia Association.

Pasricha SR, Flecknoe-Brown SC, Allen KJ, et al; Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust. 2010 Nov 1;193(9):525-32.

Prema R., 1992. Anaemia in pregnancy. In: Ratnam SS, Bhasker Rao K, Arulkumaran S, editors. Obstetrics and gynaecology for postgraduates, Vol 1. Madras: orient Longman.42-53.

Prema, R., 1989. Nutrition in Pregnancy. In: Gopalan C, Kaur S, editors. Women and nutrition in India, Special Publication No. 5. New Delhi: Nutrition Foundation of India:153-93.

Safiri, S., Kolahi, AA., Noori, M. et al. Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019. J Hematol Oncol 14, 185 (2021). https://doi.org/10.1186/s13045-021-01202-2

Scheinberg, P. and Young, N.S., 2012. How I treat acquired aplastic anemia. Blood. 120(6):1185- 96.

Sundararajan, S., Rabe, H. Prevention of iron deficiency anemia in infants and toddlers. *Pediatr Res* **89**, 63–73 (2021). https://doi.org/10.1038/s41390-020-0907-5

Toteja, G.S. and Singh, P., 2004. Micronutrient profile of Indian population. New Delhi: Indian Council of Medical Research.

Turner MR, Talbot K; Functional vitamin B12 deficiency. Pract Neurol. 2009 Feb;9(1):37-41.

U.S. Department of Health & Human Services, https://www.nhlbi.nih.gov/health/healthtopics/topics/anemia/

WHO (2004). Micronutrient deficiency: Battling iron deficiency anaemia: the challenge. Available from: http://www.who.int/nut/ida.htm, accessed on April 24, 2008

WHO, 2005. Worldwide prevalence of anaemia 1993–2005 : WHO global database on anaemia / Edited by Bruno de Benoist, Erin McLean, Ines Egli and Mary Cogswell.

Chapter 2

ACUTE MYELOID LEUKAEMIA-TYPES AND TREATMENT STRATEGIES

Dr. Rajen Dey

Email: rajend@svu.ac.in

Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal - 700121, India.

Overview:

About 80% of all occurrences of leukemia in adults are acute myeloid leukemia (AML), making it the most prevalent kind. The condition is distinguished by the clonal proliferation of immature "blast cells" in the bone marrow and peripheral circulation, leading to bone marrow failure and inefficient erythropoiesis. The cure rates have increased by up to 15% in patients over 60 and by around 40% in individuals under 60 as a result of recent improvements in the care guidelines. In the older population, prognosis is still relatively dismal despite advances in treatment regimens. We will talk about the diagnosis, classification, and potential treatments for AML in this review.

1. Introduction

An increase in myeloid cells in the bone marrow and a stop in their maturation are two characteristics of acute myeloid leukemia (AML). Bone marrow insufficiency is caused by the aberrant proliferation of leukaemic cells, which eventually replaces normal hemopoietic tissue. Anaemia, leucopenia, thrombocytopenia, or a combination of cytopenias is possible manifestations.

According to Ries et al. (1999), the incidence of AML rises with age and varies from 0.7 to 3.9 cases per 100,000 between the ages of 0 and 60, and from 6.7 to 19.2 cases per 100,000 beyond 60. AML is closely associated with radiation, past exposure to alkylating agents and epipodophyllotoxins, and exposure to chemicals like benzene, even if the exact cause of the disease is unknown. For instance, workers exposed to benzene have been found to have a ten-fold rise in AML, while Japanese survivors of the atomic bomb saw a twenty-fold increase (Preston et al, 1994). Leukemia is also more common in patients with specific congenital

conditions, including Turner's syndrome, Down syndrome, Fanconi's anemia, Klinefelter's syndrome, and Wiskott-Aldrich syndrome.

2. Classification and diagnosis of AML

The fundamental cause of the wide range of clinical signs and symptoms associated with AML is a deficiency in normal hemopoiesis. Typically, patients arrive with signs of neutropenia (infections, septicemia), thrombocytopenia (bruising and bleeding), or anemia (fatigue, dyspnea). It is not uncommon for the symptoms listed above to coexist, and on rarer occasions, additional indications and symptoms pertaining to leucocytosis, coagulopathy, skin (leukaemia cutis), or organ involvement may be more prominent at presentation.

Although any combination of anemia, thrombocytopenia, leucopenia, or leucocytosis may exist, laboratory results typically demonstrate pancytopenia. The morphological identification of myeloblasts in peripheral blood and bone marrow preparations stained with Wright-Giemsa stain is necessary for the diagnosis. These cells often have a higher ratio of nucleus to cytoplasm, are big, and have prominent nucleoli. Fine azurophilic granules and varying numbers of Auer rods may be present in the cytoplasm. The French-American-British (FAB) group's classification system for AML has been in use since 1976. It is based solely on morphological and cytochemical factors.

The direction of cell line differentiation and the level of maturity of the proliferating cells are the two parameters that determine the morphologic criteria. From MO to M7, there are eight subclassifications that are recognized: M3 acute promyelocytic leukemia, M4 acute myelomonocytic leukaemia, M5 acute monocytic leukaemia, M6 erythroleukaemia, and M7 acute megakaryocytic leukaemia. The MO subclassification is characterized by limited differentiation. The M2 subclassification is characterized by maturation. The linkage of clinical and laboratory results with treatment responses across clinical trials has been made easier for many years by the use of FAB classification. As an addition to the Wright-Giemsa stain, cytochemistry enables the visualization of particular enzymes or other materials in individual cells and identifies cells from the myeloid, monocytic, erythroid, megakaryocytic, and lymphoid lineages. Differentiating acute lymphoblastic leukemia from acute myeloid leukemia requires certain cytochemical responses (All). The M1, M2, M3, and M4 types of AML show granulocytic differentiation as revealed by the peroxidase, Sudan Black B, and

chloracetate esterase reactions; the M4 and M5 types show monocytic differentiation as revealed by the non-specific esterases and the acid phosphatase and lysozyme reactions. Periodic Acid Schiff (PAS) reaction may be substantially positive in erythroleukaemia (M6). The cytochemical profile of megakaryoblastic leukemia (M7) reveals positive responses with acid phosphatase, PAS, and a-naphthyl acetate esterase (ANAE).

Using flow cytometry for immunophenotypic analysis has proven a potent method for accurately identifying leukaemias of the myeloid and lymphoid lineages. The detection of AML in weakly differentiated and megakaryoblastic leukemias, where the blasts may be tiny and mimic lymphoblasts, is a crucial use of flow cytometry. HLA DR, CD33 (myeloid cells), CD13, CD14, and CD15 (myelomonocytic antigens), CD41, CD61 (megakaryocytic antigens), glycophorin and transferrin receptor antigens (i.e., CD71 in erythroleukaemia), and CD2, CD3, CD4, CD8, CD19, and CD20 (T and B cell antigens) are the most often used monoclonal antibodies in use for the differentiation of myeloid lineage leukaemias. Leukaemic blasts, however, might not express an expected antigen or express certain antigens of a different lineage aberrantly. For AML, cytogenetic analysis is a crucial part of the diagnosis process because atypical karyotypes are found in between 55% and 80% of newly diagnosed individuals. Primary chromosomal aberrations are generally the only karyotypic abnormality detected and are linked to a specific subtype of AML. Secondary aberrations, which result in genomic imbalances including deletions, unequal translocations, or gains or losses of entire chromosomes, are believed to be crucial in the development of the disease. Secondary aberrations may be detected at the time of diagnosis or may develop during a relapse. In AML, there are two main categories of primary chromosomal abnormalities that may be distinguished: imbalanced aberrations that result in genetic material gain or loss, and balanced structural abnormalities that typically produce a fusion transcript particular to leukemia. The t(8;21), t(l5; 17), inv(16)/t(16;16), and llq23 anomalies are the most prevalent balanced chromosomal abnormalities. The most prevalent imbalanced anomalies include trisomy 8, 11, 13, 21, 4, deletion 5q, monosomy 7, deletion 7q, deletion 9q, and deletion 8q.

The first significant prospective multi-center study to demonstrate the significance of cytogenetics as an independent prognostic factor in AML was the 4th International Workshop on Chromosomes in Leukaemia (Bloomfield et al, 1984). Subsequent research has verified that the karyotype prior to therapy is a separate predictor of achieving complete remission (CR), recurrence risk, and survival. AML patients can be assigned to one of three risk groups based on the results of three big joint studies: favourable, moderate, or unfavorable. There are

considerable variances between these three cytogenetic methods, but they all allocate numerous karyotypic anomalies to the same risk group. For instance, any aberration in the MRC classification that is not categorized as either favorable or unfavorable is placed in the intermediate risk group. On the other hand, specific abnormalities are categorized into risk groups by the Southwest Oncology Group/Eastem Cooperative Oncology Group (SWOG/ECOG) and the Cancer and Leukemia Group B (CALGB). Aberrations that are too rare to be analyzed are left as "not classified." All three cytogenetic risk methods have classified the inv(16)/t(16;16), t(8;21), and t(l5; 17) in the favorable category despite these variations. They all concur that patients with complicated karyotypes, inv(3) or t(3;3), and -7 have a bad prognosis. However, the MRC defines a complicated karyotype differently from the others; their cutoff point is three abnormalities, whilst theirs is more than four unrelated cytogenetic abnormalities. Patients with del(7q) who were not associated with -5/del(5q) or abn(3q) and who did not have a complex karyotype in the MRC study did not exhibit a statistically significant difference in outcome from patients with normal karyotypes; as a result, these patients are considered to have standard risk disease (Grimwade et al, 1998). Adult AML patients with a normal karyotype are the biggest cytogenetic category. Since their prognosis is worse than that of those with favourable risk disease, but better than that of people with poor risk disease, they are categorized as having an intermediate prognosis.

2.1. WHO classification of AML

A classification system for lymphoid and hematopoietic neoplasms was proposed by the World Health Organization (WHO) in 1999 (Vardiman et al., 2002). The classification of AML included morphologic, immunophenotypic, genetic, and clinical aspects in an effort to create biologic entities with clinical value. As of right now, there are four main kinds of AML: 1) AML with recurring genetic abnormalities, 2) AML with multilineage dysplasia, 3) AML and therapy-related myelodysplasia (MDS), and 4) AML not otherwise classified.

3. Treatment of AML

3.1. Induction chemotherapy

Even though AML was a deadly illness thirty years ago, advancements have been made since then as a result of a more aggressive treatment strategy. Eighty percent of adult patients under the age of sixty will experience complete remission (CR) under the current regimens, and a significant proportion will be cured (Grimwade et al., 1998). Cytarabine plus one of the

anthracyclines (i.e., daunorubicin, idarubicin, mitoxantrone) forms the basis of induction treatment. Although clearly proven in certain research, the usefulness of a third medication is debatable. As an illustration, the Australian Leukaemia research group demonstrated a benefit in the patient group receiving etoposide as a third medication (Bishop et al, 1990). High doses of cytarabine used in induction chemotherapy have not been shown to improve remission rates (Bishop et al, 1996; Weick et al, 1996), but they have been shown to have a positive impact on overall survival and relapse (Bishop et al, 1996).

3.2. Post induction chemotherapy

After patients reach CR, further therapy is necessary to boost survival rates and avoid relapses in the future. For younger patients, this therapy may take the form of autologous transplantation, chemotherapy, or allogeneic transplantation from sibling or other donors.

3.3. Autologous transplantation

The potential advantages of autologous transplantation over conventional chemotherapy (EORTC-GIEMMA, GOELAM, and US Intergroup) or in addition to chemotherapy (MRC) have been the subject of several studies carried out in Europe and the US (Zittoun et al, 1997; Cassileth et al, 1998; Burnett et al, 1998). Overall, all the studies have demonstrated a lower chance of relapse; however, this has not been correlated with improved survival (Harousseau et al, 1997; Burnett et al, 1998). The fact that some patients in the chemotherapy group were able to receive a transplant while in second complete remission (CR2) helps to explain this. The GOELAM and US Intergroup studies both showed improved survival in the chemotherapy arm, and it's interesting to note that high dose cytarabine was part of the treatment regimens in both trials (Harousseau et al, 1997; Cassileth et al, 1998). An alternative question, concerning the function of autologous transplantation in addition to what was deemed to be completed induction and consolidation chemotherapy, was addressed by the MRC AML 10 trial (Burnett et al, 1998). Similar to all previous trials, there was a decreased chance of relapse; however, this was offset by a significant risk of death during the surgery, meaning that overall survival did not increase.

However, as the follow-up period surpassed the second year, a survival advantage did become evident because patients primarily die from transplant-related toxicity in the first two years after the transplant, which reduces the survival benefit. Relapse is still a key reason for treatment failure even though there is evidence that recipients of autologous transplants have

a lower chance of relapse. This higher risk of relapse may be explained by residual disease as well as stem cell contamination by the tumor cells. Because of this, a lot of effort has gone into developing strategies to remove tainted cells from bone marrow and peripheral blood stem cells; in vitro purging techniques have been used (Gorin et al, 1990). This approach has not gained widespread acceptance despite some promising findings, particularly when comparable regimens employing unpurged marrow yielded comparable outcomes.

3.4. Allogeneic transplantation

Though generally safe, autologous transplantation's use is constrained by the absence of a graft-versus-leukemia (GVL) effect. On the other hand, evidence from registries or individual institutions over the past two to three decades have shown that allogeneic transplantation brings a strong GVL effect. The increased recurrence risk in recipients of T-cell deficient transplants and identical twin transplants provides additional proof that the GVL effect is present (Gale et al, 2005). The link between acute or chronic graft-versus-host disease (GVHD) and a lower risk of relapse, as shown by nearly all studies, is the strongest evidence, though (Ringden et al, 2000). Allogeneic transplantation is without a doubt the most effective anti-leukaemic treatment available, significantly reducing the risk of relapse; nevertheless, its usefulness is still debatable. First off, the potential advantages of allogeneic transplantation are compromised by the procedure's higher toxicity. Second, compared to individuals who never receive the transplant due to an early recurrence, transplant recipients are chosen and might have better disease outcomes.

Using an intention-to-treat approach, researchers have attempted to assess the transplant's possible efficacy while mitigating a number of bias factors. Adult AML patients have participated in four significant prospective trials, all of which have shown that the transplant arm has a lower chance of relapse than chemotherapy (Keating et al, 1998). However, not all studies found a true survival benefit from this lower incidence of relapse. As a matter of fact, participants in the chemotherapy arm of one trial (the US Intergroup study) demonstrated a somewhat better prognosis than those in the transplant arm (Cassileth et al, 1998). However, these differences may be accounted for by a small number of patients and insufficient transplant allocation adherence. As of right now, transplantation in first remission is not recommended in the UK for diseases with good risk (Burnett et al., 1998). Allogeneic transplantation is entirely justified in low-risk diseases when effective chemotherapy is not available, and every attempt should be made to administer the transplant as soon as possible

once remission is reached. Novel techniques will be required in this group to maximize a potential survival benefit, since the risk of relapse is significant even after transplantation. Lastly, there is insufficient evidence to justify the routine use of an allogeneic transplant in CR1 patients with standard risk illness. Given that chemotherapy seems to be improving patient outcomes over time, there will likely be increased debate on the place of allografts in normal risk diseases. However, it's possible that the limitations of traditional chemotherapy have been reached, in which case new strategies will likely be required to boost survival rates at the lowest possible toxicity cost. More research is necessary to determine the effectiveness of the recently established reduced intensity conditioning regimens in AML, as they have previously been demonstrated to be linked with low toxicity (Martino et al., 2002).

3.5. Treatment of relapses

The duration of the patient's initial remission and age are key factors in determining survival after relapse. Relapsed disease has no set course of treatment; instead, several regimens are employed. Re-induction is intended to return the patient to remission prior to bone marrow transplantation. In fact, between 25% and 30% of patients may be saved if a transplant can be administered during the second remission. However, recurrence after a transplant is still a significant factor in treatment failure, and patients in this group may benefit from additional experimental therapies.

4. Conclusion and future direction

Without a question, immunotherapy and cancer-targeted therapy have entered a new era. Potential therapeutic targets are the metabolic and enzymatic processes impacted by the genetic abnormalities. The first human malignant disease model to be reversed by a differentiation agent is Acute promyelocytic leukemia (APL), which is treated with all trans retinoic acid (ATRA). The fusion protein PML-RARA blocks the interchange of corepressors and coactivators; however, a pharmacologic dosage of ATRA reverses this blockage. Numerous studies have shown positive clinical outcomes from ATRA clinical trials for the treatment of APL, all demonstrating the drug's high efficacy and low toxicity (Fenaux et al.,



Fig. MYELOID LEUKAEMIA (Adopted from Aftab et al., 2021)

1993). 23 of the 24 patients with APL who were included in the initial publication by Huang et al. (1998) attained either complete remission or partial remission (PR) without experiencing bone marrow hypoplasia. Myeloid leukaemia development has been linked to mutations and dysregulation of Ras (Reuter et al, 2000). Another example of targeted therapy for AML is the use of famesyl transferase inhibitors, which block the post-translational modification of ras to impede subcellular localization required for signal transduction (Lancet et al, 2003). Novel medicines can also target cell surface antigens. Gemtuzumab ozogamicin is the first of these novel targeted agents to receive FDA approval in the United States. This substance is an immunoconjugate comprising an anti-CD33 antibody that has been chemically bonded to calicheamicin, a highly effective cytotoxic toxin (van Der Velden et al, 2001). WT1 (Wilms tumour) peptides specific for the HLA-A2 and A24 alleles are also being used in clinical trials as vaccines in Europe and Japan, albeit the findings have not yet been released.

References

Aftab, Muhammad & Awan, Mazhar & Khalid, Shahid & Javed, Rabia & Shabir, Hassan. (2021). Executing Spark BigDL for Leukemia Detection from Microscopic Images using Transfer Learning. 216-220.

Bishop, J,F., Matthews, J.P., Young, G.A., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M.M. & Fox, R. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87, 1710-1717.

Bishop, J.F., Lowenthal, R.M., Joshua, D., Matthews, J.P., Todd, D., Cobcroft, R., Whiteside, M.G., Kronenberg, H., Ma, D. & Dodds, A. (1990) Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood, 75, 27-32.

Bloomfield, C.D., Goldman, A., Hassfeld, D. & de la Chapelle, A. (1984) Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genetics Cytogenetics, 11, 332-350.

Burnett, A.K., Goldstone, A.H., Stevens, R.M., Hann, I.M., Rees, J.K., Gray, R.G. & Wheatley, K. (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission:

results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet, 351, 700-708.

Cassileth, P.A., Harrington, D.P., Appelbaum, F.R., Lazarus, H.M., Rowe, J.M., Paietta, E., Willman, C., Hurd, D.D., Bennett, J.M., Blume, K.G., Head, D.R. & Wiemik, P.H. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New England Journal of Medicine, 339, 1649-1656.

Fenaux, P., Le Deley, M.C., Castaigne, S., Archimbaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M.T. & Bowen, D. (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood, 82, 3241-3249.

Gale, R,E., Hills, R., Kottaridis, P.D., Srirangan, S., Wheatley, K., Burnett, A.K. & Linch, D.C. (2005) No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients excluding acute promyelocytic leukemia from the UK MRC AML 10 and 12 trials. Blood, 106, 3658-3665.

Gorin, N.C., Aegerter, P., Auvert, B., Meloni, G., Goldstone, A.H., Burnett, A., Carella, A., Korbling, M., Herve, P. & Maraninchi, D. (1990) Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood, 75, 1606-1614.

Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322-2333.

Harousseau, J.L., Cahn, J.Y., Pignon, B., Witz, F., Milpied, N., Delain, M., Lioure, B., Lamy, T., Desablens, B., Guilhot, F., Caillot, D., Abgrall, J.F., Francois, S., Briere, J., Guyotat, D., Casassus, P., Audhuy, B., Tellier, Z., Hurteloup, P. & Herve, P. (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood, 90, 2978-2986.

Huang, M.E., Ye, E.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhoa, L., Gu, L.J. & Wang, Z.Y. (1998) Use of alltrans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood, 72, 567-572.

Keating, S., de Witte, T., Suciu, S., Willemze, R., Hayat, M., Labar, B., Resegotti, L., Ferrini, P.R., Caronia, F., Dardenne, M., Solbu, G., Petti, M.C., Vegna, M.L., Mandelli, F. & Zittoun, R.A. (1998) The influence of HLAmatched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8 A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. British Journal of Haematology, 102, 1344-1353.

Lancet, J.E. & Karp, J.E. (2003) Famesyl transferase inhibitors in myeloid malignancies. Blood Reviews, 17, 123-129.

Martino, R., Caballero, M.D., Simon, J.A., Canals, C., Solano, C., Urbano-Ispizua, A., Bargay, J., Leon, A., Sarra, J., Sanz, G.F., Moraleda, J.M., Brunet, S., San Miguel, J. & Sierra, J. (2002) AML and alloPBSCT Subcommittees of the Spanish Group for Hematopoietic Transplantation Evidence for a graftversus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood, 100, 2243-2245.

Preston, D.I., Kusumi, S., Tomonaga, M., et al: (1994) Cancer incidence in atomic bomb survivors: part III. Radiaiot Res 137, 68-S97, (suppl).

Reuter, C.W., Morgan, M.A. & Bergmann, L. (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood, 96, 1655-1669.

Ries, L.A., Kosary, C.L., Hankey, B.F., Miller, B.A., Clegg, L.X., eds. (1999) SEER Cancer Statistics Review, 1973-1996. NIH publication 99-2789. Bethesda, MD: National Cancer Institute.

Ringden, O., Labopin, M., Gorin, N.C., Schmitz, N., Schaefer, U.W., Prentice, H.G., Bergmann, L., Jouet, J.P., Mandelli, F., Blaise, D., Fouillard, L. & Frassoni, F. (2000) Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients

undergoing bone marrowtransplantation for acute leukaemia? British Journal of Haematology, 111, 1130-1137.

van Der Velden, V.H., te Marvelde, J.G., Hoogeveen, P.G., Bernstein, I.D., Houtsmuller, A.B., Berger, M.S. & van Dongen, J.J. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells Blood, 97, 3197-3204

Vardiman, J.W., Harris, N.L. & Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood' 100, 2292-2302.

Weick, J.K., Kopecky, K.J., Appelbaum, F.R., Head, D.R., Kingsbury, L.L., Balcerzak, S.P., Bickers, J.N., Hynes, H.E., Welbom, J.L., Simon, S.R. & Grever, M..A. (1996) randomized investigation of high-dose versus standarddose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood, 88, 2841-2851.

Zittoun, R., Suciu, S., Watson, M., Solbu, G., Muus, P., Mandelli, F., Stryckmans, P., Peetermans, M., Thaler, J., Resegotti, L., Dardenne, M., Willemze, R. (1997) Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant, 20, 307-315.

Chapter 3

An In-Depth Analysis of Thalassemia: Causes, Diagnosis & Management

Mr. Rupak Bera

email: rupakb@svu.ac.in

Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal-700121, India

3.1 Overview :-

Thalassaemia, a hereditary blood disorder, manifests in various forms ranging from asymptomatic to severe or life-threatening conditions. While modern treatments offer promising outcomes for severe cases, lifelong monitoring and therapy remain essential to mitigate complications. Predominantly prevalent among individuals of Mediterranean or Asian descent, thalassaemia can be detected through blood tests. Early diagnosis, particularly for pregnant women and couples planning a family, is advised to facilitate timely intervention. In India, thalassaemia screening is recommended for all pregnant women and newborns, although individuals can opt for testing prior to conception.

3.2 Definition of Thalassaemia:-

Thalassaemia is a hereditary (genetic) condition that impacts the blood. It encompasses various types, with some forms presenting no symptoms while others can lead to severe, lifelong health challenges that necessarily needs treatment.

3.3 Classification of Thalassaemia:-

Hereditary abnormalities in haemoglobin, known as thalassaemia, can be categorized in various ways. The primary classifications include alpha thalassaemia and beta thalassaemia, where "alpha" and "beta" denote the affected haemoglobin gene and the faulty haemoglobin chain, respectively. Additionally, there are less common types of thalassaemia.

Each type of thalassaemia (alpha and beta) is further delineated into subtypes based on the severity of the condition, primarily determined by the number of thalassaemia genes involved. The mildest forms are referred to as thalassaemia trait (or thalassaemia minor). Among the more severe beta types are beta thalassaemia major (BTM) and beta thalassaemia

intermedia (BTI). Similarly, the more severe alpha forms include Hb Barts (very severe) and HbH disease (moderate).

Furthermore, there exist rarer types of thalassaemia such as delta beta thalassaemia, or combinations involving a beta-thalassaemia gene with another abnormal haemoglobin gene like HbE.

3.3.1 Thalassaemia trait (thalassaemia minor):

This indicates that individuals carry a thalassaemia gene but are capable of producing adequate normal haemoglobin. Consequently, these individuals typically do not experience any symptoms or complications related to thalassaemia and may remain unaware unless undergoing specific blood tests. However, knowledge of this diagnosis can be beneficial for several reasons:

- Certain types of thalassaemia trait may result in a very mild form of anemia characterized by smaller red blood cells with more central pallor than usual (referred to as 'microcytic and hypochromic'). This presentation can be mistaken for iron deficiency anemia.
- While this mild form of thalassaemia trait does not pose a significant health concern on its own, if both parents carry a similar gene, there's a possibility of their offspring inheriting a double dose of the abnormal haemoglobin gene, potentially leading to a severe form of thalassaemia. Testing for parents or even for an unborn baby can be arranged to assess the likelihood of the child being affected.

There are three types of thalassemia trait:

- Alpha plus thalassemia trait: Individuals with this trait have one missing alpha haemoglobin gene out of the usual four. This trait generally does not pose a problem unless one partner possesses alpha zero thalassaemia trait. In such cases, there's a risk of children inheriting HbH disease. Otherwise, this trait typically does not affect offspring.
- Alpha zero thalassemia trait: Individuals with this trait have two missing alpha hemoglobin genes out of the normal four. If one partner carries alpha zero thalassemia trait, there's a potential for their children to inherit a severe condition known as Hb

Barts. Alternatively, if one partner has alpha plus thalassemia trait, offspring might inherit Hb H disease.

- Beta-thalassaemia trait: Individuals with this trait possess one abnormal beta-haemoglobin gene out of the usual two beta genes. This trait does not cause illness in the individual. However, if both partners have beta-thalassaemia trait, there's a possibility of their children inheriting beta thalassaemia major (BTM) or beta thalassaemia intermedia (BTI). Moreover, beta-thalassaemia trait can interact with other abnormal haemoglobin genes unrelated to thalassaemia. For instance, if one partner carries a gene for sickle cell anaemia, their children might inherit a serious condition known as sickle cell/beta thalassaemia.

3.3.2 Sickle cell/beta thalassaemia

This scenario arises when one parent possesses a beta-thalassaemia gene, and the other parent carries a gene for another hemoglobin disorder known as sickle cell anaemia. If their child inherits one gene for each disorder, the resulting combination is termed sickle cell/beta thalassaemia, also referred to as sickle cell disease. This condition exhibits characteristics similar to sickle cell anaemia rather than thalassaemia and is managed using the same treatment protocols as sickle cell anaemia.

3.3.3 HbH disease

This type of alpha thalassaemia, known as HbH disease, results from the absence of three alpha-haemoglobin genes, whereas individuals typically possess four of these genes. This condition can occur when one parent has alpha plus thalassaemia and the other parent has alpha zero thalassaemia. HbH disease commonly manifests as a mild yet persistent form of anaemia. In some cases, individuals with HbH disease may experience more pronounced symptoms resembling those of beta thalassaemia intermedia (BTI). Treatment for HbH disease may involve blood transfusions for certain individuals.

3.4 CAUSES OF THALASSAEMIA

The underlying cause of thalassaemia is a hereditary (genetic) alteration affecting the genes responsible for instructing the body in producing an essential chemical known as haemoglobin. Haemoglobin plays a crucial role in transporting oxygen within the blood,

imparting its characteristic red color. It is primarily housed within red blood cells, integral components of the bloodstream.

Haemoglobin consists of various components, notably alpha chains and beta chains, which combine to form the haemoglobin molecule. In thalassaemia, a segment of the haemoglobin is defective, typically involving either the alpha chains or the beta chains. This results in impaired function of some haemoglobin molecules, leading to insufficient levels of normal haemoglobin and heightened susceptibility of red blood cells to breakdown. Consequently, individuals experience anaemia due to inadequate haemoglobin levels, accompanied by various symptoms.

In response to the diminished haemoglobin levels, the body initiates compensatory mechanisms to augment haemoglobin and red blood cell production. This leads to an overproduction state within the blood system, potentially exacerbating symptoms and complications.

The extent of abnormal haemoglobin present varies depending on the type of thalassaemia, ranging from a significant proportion to a minor fraction of the body's haemoglobin. This variability primarily dictates the severity of thalassaemia. Additionally, individual-specific factors contribute to the overall clinical presentation. Consequently, two individuals with the same type of thalassaemia may exhibit differing degrees of illness despite sharing the same underlying condition.

3.5 CLINICAL SYMPTOMS OF THALASSAEMIA

The onset and manifestation of symptoms in thalassaemia vary depending on the type and severity of the condition. While some children may exhibit symptoms from birth, others may develop them within the first two years of life, or remain asymptomatic in cases where only one gene is affected.

Key symptoms may include:

- General weakness or fatigue.
- Pallor or a yellowish hue to the skin.
- Darkening of urine.
- Slow growth rate.

- Shortness of breath.
- Abdominal bloating or flatulence.
- Bone deformities.
- Recurrent infections or inflammations.

These symptoms can significantly impact the quality of life and require ongoing medical management and support.

3.6 LABORATORY DIAGNOSIS

Examination of Peripheral blood smear:



[An image of a Hemoglobin H Disease peripheral blood smear showing marked poikilocytosis (tearsdrop cells, schistocytes, target cells, and elliptocytes). 50x oil immersion. From MLS Collection, University of Alberta, https://doi.org/10.7939/R30P0X613]

- RBCs: –

The haematological features of microcytic hypochromic anemia in thalassaemia major include:

I. Moderate to marked anisocytosis and poikilocytosis: Variability in the size and shape of red blood cells (RBCs).
II. Presence of many target cells: Morphologically abnormal RBCs in which hemoglobin distribution results in a target-like appearance, with hemoglobinized periphery and central regions. This characteristic is observed in thalassaemia major, sickle cell anaemia, HbC disease, post-splenectomy status, liver disease, and obstructive jaundice.

III. Basophilic stippling: The presence of small, dark-staining granules in RBCs.

IV. Variable numbers of nucleated red cell precursors (normoblasts), ranging from 5% to 40%.

- White blood cell count (WBCs):

I. Leukocytosis with a mild left shift, indicating an increase in the number of white blood cells with a slight shift towards immature forms.

- Platelet count:

  Typically within the normal range.

3.7 PREVENTIVE MEASURE

The prevention of thalassaemia major in children primarily relies on identifying the thalassaemia status of both parents before conception. If both parents test positive for the carrier state, they should undergo counseling for prenatal diagnosis during the first trimester of pregnancy to determine whether the fetus is affected. In cases of an affected fetus, medical termination of the pregnancy is often advised to the couple.

Treatment for thalassaemia major typically involves:

1. Blood transfusions: Most individuals with thalassaemia major or other severe forms require regular blood transfusions to manage anaemia. This procedure entails administering blood through a tube inserted into a vein in the arm and is usually conducted in a hospital setting, taking several hours each time.

2. Stem cell or bone marrow transplants: Stem cell or bone marrow transplants represent the only curative option for thalassaemia, although they are not frequently performed due to significant associated risks. Stem cells, crucial for the formation of various blood cells, are derived from bone marrow, the spongy tissue found in certain bones.

3. Removal of excess iron: Chelation therapy is employed to eliminate excess iron resulting from recurrent blood transfusions. This therapy is essential as elevated iron levels in the body can lead to organ damage.

3.8 TREATMENT

The treatment approach for thalassaemia varies based on the type and severity of clinical condition. For mild to severe cases, treatment options may include:

- Blood transfusion: Regular red blood cell transfusions are the primary therapy for individuals with moderate to severe thalassaemia. These transfusions help replenish the deficient red blood cells and alleviate symptoms of anaemia.
- Stem cell transplant (bone marrow transplant): Stem cell transplantation can be utilized to treat severe forms of thalassaemia. This procedure involves replacing diseased bone marrow with healthy stem cells from a compatible donor, aiming to restore normal blood cell production.
- Management of iron overload: Excess iron accumulation in the body is a common consequence of recurrent blood transfusions. Doctors employ various methods to remove excess iron, including chelation therapy. Chelation therapy involves administering medications to bind and eliminate excess iron from the body. Some medications may be administered orally or through slow infusion under the skin.

Individualized treatment plans are tailored to meet the specific needs of each patient, taking into account factors such as the type and severity of thalassaemia, overall health status, and treatment goals.

REFERENCES:

1. Viswanadham Manasa, K. Vanitha, M. Venkataswamy, P. Prabhakar, Alluri Ramesh "Formulation and Evaluation of Aqueous Enteric Coated Delayed Release Omeprazole Pellets" Research Journal of Pharmaceutical Dosage Forms and Technology, A and V publications, 8(1): January-March, 2016, (1- 4).

2. K. Vyshnavi, Madhuri Bhashetty, Namitha Swain, M. Venkataswamy, Alluri Ramesh "Evaluation of Prepared Aspirin Modified Release Tablets with Polymer Isolated from Fresh Mosambi Leaves" Research Journal of Pharmaceutical Dosage Forms and Technology, A and V Publications, 9(2): April- June, 2017.

3. M. Venkataswamy, Arul B, Keerthi Sagar A, Dinesh Mohan S, Vanitha K, Ramesh Alluri "Preparation and Evaluation of a Mucoadhesive Polymer from the Extract of Seeds of Annona squamosa Linn" Asian J. Res. Pharm. Sci., A and V Publications, 2017; Vol. 7: Issue 3.

4. Chiluveri Sanjuna, Pindrathi Pravalika, Chikoti Sneha Priya, M. Venkataswamy, Alluri Ramesh. The Insidious Disease from Insects: Lyme disease. Research Journal of Pharmaceutical Dosage Forms and Technology. A and V Publications 2018; 10(1): 17-22.

5. K. Prathyusha, Jaggareddy Gari Manasa Reddy, M. Venkataswamy, Alluri Ramesh "Pico technology: Instruments used and Applications in pharmaceutical field" Research Journal of Pharmaceutical Dosage Forms and Technology, A and V Publications, 10(1): January-March, 2018, (34-41).

6. Jaggareddy gari Manasa Reddy, K. Prathyusha, M. Venkataswamy, Alluri Ramesh, "Spreading of Swine flu disease: Past and Present" Research Journal of Pharmaceutical Dosage Forms and Technology, A and V Publications, 10(2): April- June, 2018.

7. K. Vanitha. M. Venkataswamy, Sanam Niharika, Alluri Ramesh. Formulation Development and Evaluation of Mebeverine extended release Pellets. Asian J. Pharm. Tech. A and V Publications, 2018; 8 (2):71-77.

8. M. Venkataswamy, M. Santhoshini, J. P. Priyanka, K. Prathyusha, Jaggareddy Gari Manasareddy and Ramesh Alluri "preparation and evaluation of biphasic bilayered buccal tablet containing ketorolac immediate release layer and domperidone maleate sustained release layer" World Journal of Pharmaceutical Research, Volume 7, Issue 11, 905-949.

9. M.Venkataswamy, S. Naveen Kumar, B. Ramesh, G. Anantha Ramulu, M. Bharath, K. Sridivya Goud “Preparation and Evaluation of Mucilage from Fresh Leaves of Psidium Guajava” Research Journal of Pharmaceutical Dosage Forms and Technology, A and V Publications, 10(3): July- September, 2018.

10. M.Venkataswamy, Neha Thahaseen, MD Kareemuddin, JP Priyanka, Jaggareddy Gari Manasa Reddy “Formulation And Evaluation of sustained release matrix tablets using drug Cytisine isolated from Fava Beans to quit Smoking” Research Journal of Pharmaceutical Dosage Forms and Technology, A and V Publications, 10(3): July- September, 2018.

11. Ifath Jabeen, M. Venkataswamy, Jawariya Sadaf, Maistry Nishitha Reddy, A.V. Naga Mallika, Mamidi Sushmitha, “Drug abuse, addiction, its causes and treatment”, Research Journal of Pharmaceutical Dosage Forms and Technology, A and V Publications, 10(3): July-September, 2018.

12. Mallik, R., Sing, D., & Bandyopadhyay, R. (2020). GPS Tracking App for Police to Track Ambulances Carrying COVID-19 Patients for Ensuring Safe Distancing. *Transactions of the Indian National Academy of Engineering : an international journal of engineering and technology*, *5*(2), 181–185. https://doi.org/10.1007/s41403-020-00116-8

13. Thalassemia International Federation. Guidelines for the clinical management of thalassemia. 2. 2008. http://www.thalassemia.org.cy.

14. Galanello R, Piras S, Barella S, Leoni GB, Cipollina MD, Perseu L, Cao A. Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassemia. Br J Haematol. 2001; 115:926–928. doi: 10.1046/j.1365-2141.2001.03200x.

15. www.practo.com/health-wiki/thalassemia-causes-symptoms-and treatment/28/article.

16. Cianciulli P (October 2008). "Treatment of iron overload in thalassemia". Pediatr Endocrinol Rev. 6 (Suppl 1): 208–13.

17. Rahamat Unissa, Bayyaram Monica, Sowmya Konakanchi, Rahul Darak, Sandagalla Lipi Keerthana, Saranya Arun Kumar. Thalassemia: A Review . Asian J. Pharm. Res. 2018; 8(3): 195-202. doi: 10.5958/2231-5691.2018.00034.5.

18. Vogiatzi, M. G., Macklin, E. A., Fung, E. B., Cheung, A. M., Vichinsky, E., Olivieri, N., Kirby, M., Kwiatkowski, J. L., Cunningham, M., Holm, I. A., Lane, J., Schneider, R., Fleisher, M., Grady, R. W., Peterson, C. C., Giardina, P. J., & Thalassemia Clinical Research

Network (2009). Bone disease in thalassemia: a frequent and still unresolved problem. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, *24*(3), 543–557. https://doi.org/10.1359/jbmr.080505

19. "Symptoms and Causes - Enlarged spleen (splenomegaly) - Mayo Clinic". www.mayoclinic.org. Archived from the original on 19 November 2016. Retrieved 2 February 2017.

20. Soliman, A. T., De Sanctis, V., & Kalra, S. (2014). Anemia and growth. *Indian journal of endocrinology and metabolism*, *18*(Suppl 1), S1–S5. https://doi.org/10.4103/2230-8210.145038

21. Kirkham, J. K., Estepp, J. H., Weiss, M. J., & Rashkin, S. R. (2023). Genetic Variation and Sickle Cell Disease Severity: A Systematic Review and Meta-Analysis. *JAMA network open*, *6*(10), e2337484. https://doi.org/10.1001/jamanetworkopen.2023.37484

Chapter 4

AN IN-DEPTH INVESTIGATION OF RISK FACTORS ASSOCIATED WITH SEPSIS AND THE POTENTIAL TREATMENT MODALITY

Mr. Manojit Bysack
Email: monojitb@svu.ac.in

Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal-700121, India

Overview:
In order to lower mortality, Sepsis and septic shock have a time-varying, potentially fatal illness that needs to be treated quickly. The treatment of sepsis/septic shock is difficult and involves several pathophysiological elements. These include the use of vasoactive agents, such as norepinephrine (NE), combined with empirical antibiotic therapy, which is promptly given after microbiological testing, to maintain mean arterial pressure above 65 mmHg and reduce the danger of fluid overload, and fluid replacement (crystalloids), and fluid tolerance and responsiveness. Vasopressin, not epinephrine, should be used in conjunction with NE to achieve a satisfactory degree of pressure control in cases with refractory shock. The tidal volume should be lowered from 10 to 6 mL/kg if mechanical ventilation is recommended. To avoid venous thromboembolism, heparin is given, and glucose management is advised. Although the effectiveness of various treatments (such as sodium bicarbonate, proton-pump inhibitors, etc.) is hotly contested, they may be utilized on an individual basis. Recent years have seen a major advancement in the management of sepsis and septic shock. To improve patient outcomes, it is imperative to increase understanding of the key therapeutic pillars of this difficult condition.

1. Introduction:

According to definitions, sepsis is a sickness that is caused by endogenous factors in reaction to bacterial, viral, parasite, or fungal infections and consists of intricate pathophysiological and biochemical abnormalities. The recent advancements in our comprehension of the underlying pathophysiology based on molecular and clinical investigations have led to

revisions and adjustments to the definition of sepsis. According to modern definitions, sepsis is "a dysregulated host immune response to infection resulting in life-threatening organ dysfunction." (5) in accordance with the revised definition. A severe illness known as sepsis results from the body's immune system reacting excessively to an infection. The tissues and organs of the body suffer harm as a result of the reaction. Anyone can have sepsis, but those who are extremely young, elderly, pregnant, or suffering from other medical conditions are more likely to get it. Fever, an accelerated heartbeat, rapid breathing, disorientation, and bodily discomfort are typical indicators of sepsis. Septic shock, multiple organ failure, and even death are possible outcomes. Although bacterial infections are the most common cause of sepsis, infections from viruses, parasites, or fungus can also result in the condition. Sepsis treatment necessitates medical attention. Antimicrobials, intravenous fluids, and close observation are all part of it. One of the most common adverse outcomes during the provision of care is sepsis acquired in a healthcare context, which affects hundreds of millions of patients annually worldwide. Healthcare-associated infections are brought on by organisms or pathogens that can quickly worsen clinical conditions and are frequently resistant to medication. One of the main factors influencing clinical resistance to therapy and the quick development of sepsis and septic shock is antimicrobial resistance. Hospital mortality has been observed to be greater in sepsis patients with resistant infections. Key steps in lowering the incidence of sepsis include putting infection prevention and control best practices into practice in both community and healthcare settings. These include maintaining access to immunization programs, improving sanitation, improving water quality and availability, and implementing good hygiene practices. To improve the prognosis, sepsis must be identified early and treated appropriately in the clinic. This includes using the best available antibiotics and performing fluid resuscitation. Sepsis can cause severe long-term morbidity that requires treatment and support, despite the fact that its initial onset can increase the risk of short-term mortality. A comprehensive approach is thus necessary for sepsis. Sepsis can be brought on by severe injury, infection, or serious non-communicable disease; however, certain populations are more vulnerable than others: the elderly, women who are pregnant or who have recently become pregnant, neonates, hospitalized patients, patients in intensive care units, individuals with weakened immune systems (such as those with HIV or cancer), and those with long-term illnesses (such as cirrhosis or kidney disease) (1, 2, 3, 4).

2. Signs and Symptoms:

A medical emergency is sepsis. It may produce various symptoms and indicators at various periods. Those who suspect sepsis should get help as soon as possible. Frequent indications and manifestations encompass: Disorientation, breathing difficulties, hot and clammy skin, fever or low body temperature and shivering, severe bodily pain or discomfort, raised heart rate, weak pulse or low blood pressure, and decreased urine production. Pale skin, pale breathing, convulsions, fatigue, difficulty waking up, and a cold sensation to the touch are among the symptoms that affect children. In children under five, it may cause feeding issues, frequent vomiting, or lack of urine (1, 2, 3, 4).

3. Causes:

In 2017, diarrheal diseases (9.2-15.2 million cases annually) and lower respiratory infections (1.8–2.8 million cases annually) accounted for the majority of sepsis cases and sepsis-related deaths across all age categories. Non-communicable disorders, however, are becoming more prevalent; in 2017, an underlying injury or chronic condition accounted for one-third of sepsis cases and nearly half of all sepsis-related deaths. The most prevalent non-communicable disease that was exacerbated by sepsis was maternal disorders. Lower respiratory infections, diarrheal illnesses, and newborn abnormalities were the most common causes of sepsis-related mortality in children. Sepsis in both neonates and mothers is most commonly caused by Group B streptococcus, while Escherichia coli is becoming a more serious hazard. Due to their significant treatment resistance, these diseases are prioritized for investigation and the creation of novel antibiotics (1, 2, 3, 4).

4. Pathogenesis:

Because of space limitations, only a brief synopsis of the complicated pathophysiology of sepsis (33, 34) can be provided here. The discovery in a seminal 1986 study that the host cytokine tumour necrosis factor (TNF, also called cachectin) could recapitulate many of the pathological and clinical characteristics of sepsis was a significant conceptual advance (35). Lewis Thomas first noticed this in 1972, and given that a range of bacterial and other pathogen products might release TNF, it was evident that the host's response to the infection had a significant part in the development of the sickness. Subsequent research has demonstrated that a complex network of cytokines has a significant role in modulating a

number of sepsis-related symptoms. Even while the early pro-inflammatory pathways are crucial, anti-inflammatory pathways are also active and have the capacity to suppress corrective responses later on in sepsis. A wide range of additional mediators, such as prostanoids, platelet activating factor, and endogenous damage-associated molecular patterns (DAMPS) produced by wounded cells, such as ATP and high mobility group proteins, are also implicated in addition to protein and peptide mediators. By highlighting specific elements of this intricate pathogenic process—like the four horsemen of the septic apocalypse—it is feasible to make it simpler.

4.1. Endothelial dysfunction

Increased leucocyte transmigration into tissues is accompanied by the production of many leucocyte adhesins upon generalized endothelial activation. Increased endothelial permeability can also cause interstitial pulmonary edema in the lung and enhance bacterial translocation in the gut, which can exacerbate inflammatory cascades that are already set off by microbial products.

4.2. Coagulopathy

Sepsis frequently causes coagulation abnormalities. Endothelial injury changes the endothelium into a prothrombotic surface by eliminating the protective role of the natural anticoagulant protein C pathway. Moreover, tissue factor, the primary activator of the extrinsic pathway of blood coagulation, is activated by bacterial products and inflammatory cytokines. This prothrombotic disease can clog the microvasculature as well as cause disseminated intravascular coagulation, also referred to as consumption coagulopathy. Additionally, the contact clotting system can be directly activated by gram-positive materials.

4.3. Cellular dysfunction

Despite widespread organ malfunction, autopsy investigations reveal no evidence of cell death even in the most severe cases of deadly sepsis, which is one of the field's mysteries. Though a generalized decrease in cell energy consumption points to some sort of hibernation-like phenomenon, the molecular basis of this is yet unclear. Many metabolic alterations, most notably elevated catabolism, insulin resistance, and hyperglycemia, occur concurrently with this modification in cellular function.

4.4.Cardiovascular dysfunction

According to a number of studies, patients in the so-called "hyperdynamic" stage of sepsis exhibit reduced systemic vascular resistance (SVR) and either normal or enhanced cardiac output. Reduced ejection fraction and lower left ventricular stroke work index in response to an increase in left ventricular end diastolic volume conserve cardiac output at the cost of left ventricular dilatation. The hypotension that characterizes septic shock may result from these alterations. Variations in SVR are most likely primarily caused by the vasculature's overproduction of the vasodilator nitric oxide, which can be challenging to regulate with vasopressors (12). The elevated lactate observed in septic shock is also likely caused by poor tissue perfusion, though there may be other explanations.

5. Diagnosis:

In terms of the host response, which is dysregulated, widespread, and characterized by nonspecific signs and symptoms, sepsis is distinct from localized microbial infection [6]. One common clinical reaction that signals the start of a host response is fever. On the other hand, severely ill individuals frequently experience hyperthermia, which is not always a sign of infection. Furthermore, leukopenia and tachycardia might be symptoms of various underlying clinical disorders or they can be present in severely ill patients. Most frequently, in patients with hypoxia, sepsis may go undiagnosed, and in postoperative patients receiving antibiotic therapy who exhibit fever, low platelet counts without any indication of infection may result in an overdiagnosis [7, 6]. This led to the discovery that the systemic inflammatory response syndrome (SIRS) criteria were unreliable, and it is not advised to use them for diagnosing sepsis [8, 15]. Culture reports from bodily fluids, especially blood, are the most confirmatory and reliable method of diagnosis in addition to symptom-based diagnosis; however, their early clinical value is limited by the assay time of 24 to 48 hours [9, 15]. Regrettably, colony-forming units below detectable levels or previous/continuous antibiotic therapy may be to blame for the 30–40% of suspected sepsis cases of infected patients that are discovered to be culture-negative [8, 10, 15]. Therefore, a major area of study in sepsis diagnosis is tracking using accurate biomarkers that will enable early treatment intervention and improved patient outcomes, as a result of the aforementioned diagnostic problems. Sepsis biomarkers are useful in determining whether an infection is present or not, the severity of the illness, and how well the patient is responding to treatment [6, 15]. Although it has a high sensitivity, its lack of specificity limits its use in the diagnosis of sepsis. C-reactive protein (CRP) is an acute-phase protein that has been extensively investigated. It is elevated by both infection and

inflammation. Procalcitonin (PCT), which has also been widely reported, may be a more specific marker than CRP when it comes to systemic inflammation brought on by a bacterial infection [11, 15]. Nonetheless, it has been discovered that the levels of these biomarkers are influenced by other non-inflammatory conditions such burns, pancreatitis, or traumas. It is unsuitable to use a single biomarker for the diagnosis of sepsis because to the proven complexities and varying timeframes of individual biomarker expression, particularly in patients who are critically unwell. The development of biomarker panels or combinations for the diagnosis of sepsis is an emerging field of research that demonstrates greater reliability than individual biomarkers. More research is necessary to optimize the biomarker combinations, though. Additionally, patient classification is essential since, as we've already discussed, a more individualized strategy will mitigate the negative effects of patient heterogeneity. A series of pro- and anti-inflammatory cytokines are linked to sepsis, and their prevalence varies depending on the stage of the disease. When dealing with a diverse group of patients, nano-diagnostic techniques hold promise as quick and accurate means of detection. Consequently, early biomarker analysis can be used to stratify patients, which could aid in the implementation of tailored medications [12, 15]. New avenues for the detection and treatment of critical illness are being opened up by the application of nanotechnology-based solutions for clinical problems [13, 15]. The field of antibiotics could undergo a revolution as a result of the potential that nanotechnology has demonstrated to combat microbial illnesses, especially those brought on by pathogens with resistance [14, 15].

6. Preventive Measures:

Good hygiene both at home and in medical facilities, along with early treatment of infections, can help prevent sepsis. By avoiding infections, one can lower the chance of sepsis the best. Vaccinations prescribed by local health officials should be obtained; maintaining a nutritious diet; nursing for newborns; practicing excellent personal hygiene, like cleaning your hands and cooking food properly; avoiding unclean water and unsanitary toilets. In order to prevent and control infections, hospitals and clinics should adhere to appropriate guidelines. Treatment of infections with antibiotics should be done carefully. HIV, TB, malaria, and other infectious disease patients are more vulnerable to sepsis, which is usually a dangerous illness (1, 2, 3, 4).

7. Management of sepsis:



The three components of septic shock management. *SOSD* salvage, optimization, stabilization, and de-escalation

Fig: Management of Sepsis (Adopted from 37)]

Guidelines based on evidence were lacking for the early therapy of septic shock and severe sepsis before to 2001 (16). In the past, doctors focused on oxygen delivery and cardiac index supra physiological values in severely ill sepsis patients (17–19). Gattinoni et al. came to the conclusion that goal-oriented care of this kind does not lower morbidity or death rates in patients who are critically sick. According to a number of further investigations, intensive efforts to raise cardiac index and oxygen delivery hemodynamic values did not appear to improve patient outcomes (20, 21). Beal and Cerra realized that effective shock resuscitation might stop sepsis from progressing to multiple organ failure. The foundation of early goal-directed therapy was the notion that sepsis, severe sepsis, and the severe inflammatory response syndrome (SIRS) were all components of an ongoing process, and that SIRS might be reduced with prompt intervention. Critical "golden hours" of sepsis are defined by Rivers et al. as the period immediately preceding the sudden switch to serious disease and the start of early goal-directed therapy (EGDT). High-risk patient identification, proper cultures, source control, and early antibiotic therapy were the cornerstones of EGDT. Early hemodynamic optimization of oxygen supply and lowering oxygen use came next (19). Targets for early resuscitation for sepsis-induced hypoperfusion included 0.5 mL kg−1 h−1, 65 mmHg mean arterial pressure, 8–12 mmHg central venous pressure, and 70% or 65% mixed venous saturation (ScvO2) or superior vena cava oxygen saturation (MvO2), respectively (22, 23). When EGDT was used within the first six hours of resuscitation for patients presenting to the emergency room with severe sepsis or septic shock, Rivers et al. saw an absolute 15.9% decrease in the 28-day death rate (22–24). The 2004 Surviving Sepsis Campaign guidelines, which cover the first 6-hour sepsis resuscitation bundle, included the EGDT. (25-27). Subsequent studies using EGDT or a sepsis resuscitation bundle showed a comparable 28-day mortality decrease (28, 29). Some researchers continued to have doubts about the EGDT study's design and treatment objectives (30). Unlike traditional treatment, EGDT used central venous catheterization, which was essential for monitoring CVP and

ScvO2. This allowed for the administration of intravenous fluid, vasopressors, packed red cell transfusions, and dobutamine to be directed toward the predefined physiological targets (22, 31). The way sepsis is managed has changed over twenty years after the Rivers experiment, and overall mortality from severe sepsis has decreased (32).

8.Possible Mode of Treatment:

The best results from sepsis treatment come from early initiation. To diagnose sepsis, medical professionals look for alarming symptoms and perform testing. Next, they will endeavor to identify the infection's origin. To enhance sepsis outcomes, antimicrobial therapy administered early on must target bacteria, parasites, fungi, or viruses. Intravenous fluids are used to treat low blood pressure, and medications known as vasopressors are occasionally used to raise blood pressure. Treatment difficulties may arise from antibiotic resistance (1,2,3,4). Even though sepsis is a condition that is time-dependent and potentially fatal, the prognosis is often not good. Sepsis and septic shock provide difficulties for emergency physicians in their day-to-day work for a number of reasons: There are three main factors that contribute to the condition's subtle clinical onset: (i) misdiagnosis that causes treatment delays that worsen clinical outcomes and quality of life; (ii) complex and multidisciplinary management of these conditions that involves many unresolved therapeutic aspects, including when to start antimicrobial treatment, when to administer fluid resuscitation, when to administer vasopressors, and oxygen targets. However, patients' prognosis can be improved by a well-planned course of treatment that includes fluids, oxygen, antimicrobials, and, if needed, vasoactive drugs. When combined, the information included in this evaluation of sepsis management offers a solid foundation for reducing the unmet needs related to this serious illness at the moment (5).

Antimicrobials (5):

Prior to administering antimicrobials, culture samples are necessary;-Treatments ought to be initiated promptly and based on clinical/epidemiological criteria;- For an adequate reduction approach, it is advised to regularly assess patients' state and PCT levels. Short courses of antimicrobial treatment may also be required.

Fluids (5):

Small, repeated boluses (250–500 mL) of crystalloids with continuous hemodynamic monitoring are recommended, as are customized resuscitation regimens based on FT and FR. Balanced crystalloids are the recommended fluid.

Vasoactive agents (5):

When a patient's mean arterial pressure (MAP) is less than 65 mmHg even after receiving fluid replacement, vasopressors must be used; for septic patients, NE at a dose of 0.1–1.2 g/kg/min is the recommended medication; early NE administration may prevent fluid overload, which could lower mortality; and if target MAP is not reached, VP at a dose of 0.25–0.5 g/kg/min may be combined with NE.

Oxygenation & Ventilation Support (5):

For titration, the target values should be either SpO2 94–98% or SpO2 88–92% if a patient is in risk of hypercapnic respiratory failure. If NIV/MV is required, it is advised to utilize a low tidal volume (6 mL/kg). For septic patients suffering from hypoxic respiratory failure, HFNC may be employed. It is advised to begin oxygenation at 15 L/min while using a reservoir mask.

Other Treatment (5):

(1) Heparin: Patients who are not suited for heparin treatment should be treated with mechanical prophylaxis; LMWH, not UFH, should be administered to prevent VTE. (2) Insulin: To reach a glucose target of 144–180 mg/dL, insulin should be used. (3) Proton Pump Inhibitors: In order to avoid stress ulcers, PPI therapy may be required. Renal replacement therapy (RRT) is recommended for certain patient subsets exclusively, despite the fact that acute kidney injury (AKI) is a frequent consequence of sepsis. (5) Steroids - Patients with vasopressor-resistant, insufficient MAP may be prescribed hydrocortisone.

(6) Sodium Bicarbonate - Patients with severe bicarbonate levels < 5 mEq/L, pH < 7.1, or AKI stages 2 or 3 may be administered sodium bicarbonate. (7) Acetaminophen - Acetaminophen should be taken as a medication for symptoms.

9**. Conclusion:**

- Initial evaluation – Treating hypoxemia, stabilizing the airway, and establishing suitable vascular access for the prompt delivery of fluids and medications are the top

objectives for patients with sepsis and septic shock. Administering fluids and antibiotics at the same time is best, but it shouldn't take longer than 45 minutes to acquire the following:

• Standard laboratory investigations; • Serum lactate; • Arterial blood gases •Aerobic and anaerobic blood cultures from two different venepuncture sites and from every indwelling vascular access device; it is best to obtain blood cultures prior to starting antibiotics. Sputum and urine are examples of easily accessible locations for cultures. Suspect sources can be imaged.

- Initial resuscitation – We recommend intravenous fluid infusion (30 mL/kg) for patients with sepsis and septic shock instead of vasopressors, inotropes, or red blood cell transfusions, starting during the first hour and finishing within the first three hours of presentation.
    - Intravenous fluids – The best way to provide medication is by fluid boluses, which should be continued until tissue perfusion and blood pressure are adequate, pulmonary edema develops, or there is no more response. Our favorite resuscitation fluid is a crystalloid solution, such as Ringer's lactate or regular saline. If it is felt that treating or preventing the hyperchloremia that arises from giving large amounts of nonbuffered crystalloid (such as normal saline) is necessary, balanced crystalloid may be the better option.
    - Antibiotics – In cases of sepsis, we advise giving patients the best possible doses of empirical broad spectrum intravenous therapy with one or more antibiotics as soon as possible (for example, within an hour of presentation). When a medicinal agent is considered broad spectrum, it means that it has enough activity to combat a wide variety of gram-positive and gram-negative organisms, as well as, if necessary, viruses and fungi. We recommend using two separate classes of antibiotics to treat resistant organisms effectively in individuals with septic shock who are most likely suffering from gram-negative sepsis. The choice of agent is influenced by various factors such as the patient's medical history, immunological deficiencies, comorbidities, clinical setting, probable infection site, intrusive device presence, Gram stain results, and local resistance patterns. Patients who are not neutropenic should not receive antifungal medication on a regular basis.

- Monitoring – For most sepsis and septic shock patients, doctors recommend using clinical targets, such as a mean arterial pressure of 60 to 70 mmHg and a urine output of ≥0.5 mL/kg/hour, to guide fluid management.
    - Hemodynamics – Furthermore, Static tests of fluid responsiveness, such as central venous pressure of 8 to 12 mmHg or central venous oxygen saturation of ≥70 percent, may be more straightforward to obtain, even though dynamic data—such as breathing fluctuations in the radial artery pulse pressure—are preferred.
    - Laboratory – Until a clear clinical response occurs, serum lactate should be monitored (for example, every six hours). It is wise to keep track of additional indicators of the body's general reaction to infection, such as microbiology research, arterial blood gases, and standard laboratory tests.
    - Source control – After completing preliminary investigations and empirical antibiotic medication, all sepsis patients should engage in further efforts to identify and manage the source(s) of infection, ideally within 6 to 12 hours. Furthermore, in cases where therapy is ineffective or ineffective after initial response to treatment, additional inquiries concerning the removal of potentially contaminated devices, the suitability of the prescribed antibiotic regimen, or the possibility of nosocomial super infection has to be taken into account.



Fig: Treatment of Sepsis via latest evidence (Adopted from 36)

- Patients who fail initial therapy – Vasopressors are recommended for sepsis patients who do not improve their blood pressure after receiving appropriate fluid resuscitation (three litres in the first three hours, for example). Norepinephrine is the recommended starting agent. Patients who do not respond to intravenous fluid and vasopressor therapy may get additional drugs, like glucocorticoids, inotropic therapy, and blood transfusions. Red blood cell transfusions are normally reserved for individuals whose hemoglobin level is less than 7 g/dL.

- Patients who respond to therapy – For sepsis patients who have responded to therapy, we advise decreasing or stopping the rate of fluid supply, weaning off of vasopressor support, and administering diuretics if needed. We also suggest limiting the use of antibiotic therapy once pathogen identification and susceptibility data are once again accessible. Antimicrobial therapy should be tailored to individual pathogens and susceptibilities for a maximum of seven to ten days; however, certain patients may benefit from shorter or longer courses.

References:

1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, andnational sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study.Lancet (London, England). 2020;395(10219):200-11.
2. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. British Medical Journal2016.
3. Clin Infect Dis. 2017;65(suppl_2):S89-S99.
4. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues.Pediatrics. 2011;127(5):817-26.
5. Matteo Guarino 1 , Benedetta Perna 1 , Alice Eleonora Cesaro 1, Martina Maritati 2, Michele Domenico Spampinato 1 , Carlo Contini 2,† and Roberto De Giorgio 1,*,† ; 2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department.
6. Vincent J-L. The clinical challenge of sepsis identification and monitoring. PLoS Med. 2016;13(5):e1002022.

7. Ifedayo Kuye CR. Spotlight: Overdiagnosis and Delay: Challenges in Sepsis Diagnosis. https ://psnet .ahrq.gov/web-mm/spotl ight-overdiagno sis-and-delay -chall enges -sepsi s-diagn osis. Accessed 7 May 2020.
8. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent J-L. Sepsis and septic shock. Nat Rev Dis Prim. 2016;2(1):16045.
9. Carrigan SD, Scott G, Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clin Chem. 2004;50(8):1301–14.
10. Claxton A, Papafilippou L, Hadjidemetriou M, Kostarelos K, Dark P. The challenge of recognising sepsis: future nanotechnology solutions. J Intensive Care Soc. 2020;21(3):241–6.
11. Gunsolus IL, Sweeney TE, Liesenfeld O, Ledeboer NA. Diagnosing and managing sepsis by probing the host response to infection: advances, opportunities, and challenges. J Clin Microbiol. 2019;57(7):e00425-e519.
12. Lazăr A, Georgescu AM, Vitin A, Azamfirei L. Precision medicine and its role in the treatment of sepsis: a personalised view. J Crit Care Med. 2019;5(3):90–6.
13. Buxton DB. Nanomedicine for the management of lung and blood diseases. Nanomedicine. 2009;4(3):331–9.
14. Zhu X, Radovic-Moreno AF, Wu J, Langer R, Shi J. Nanomedicine in the management of microbial infection—overview and perspectives. Nano Today. 2014;9(4):478–98.
15. Amit Pant, Irene Mackraj and Thirumala Govender; Advances in sepsis diagnosis and management: a paradigm shift towards nanotechnology.
16. Nguyen HB, Jaehne AK, Jayaprakash N, et al. Early goaldirected therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE. Crit Care 2016; 20(1): 160.
17. Shoemaker WC, Montgomery ES, Kaplan E, et al. Physiologic patterns in surviving and nonsurviving shock patients: use of sequential cardiorespiratory variables in defining criteria for therapeutic goals and early warning of death. Arch Surg 1973; 106(5): 630–636.
18. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333(16): 1025–1032.
19. Shoemaker WC, Appel PL, Kram HB, et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988; 94(6): 1176–1186.

20. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330(24): 1717–1722.
21. Yu M, Levy MM, Smith P, et al. Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. Crit Care Med 1993; 21(6): 830–838.
22. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345(19): 1368–1377.
23. Zhang L, Zhu G, Han L, et al. Early goal-directed therapy in the management of severe sepsis or septic shock in adults: a meta-analysis of randomized controlled trials. BMC Med 2015; 13: 71.
24. Opal SM and Cross AS. Clinical trials for severe sepsis: past failures, and future hopes. Infect Dis Clin North Am 1999; 13(2): 285–297vii.
25. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32(3): 858–873.
26. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34(1): 17–60.
27. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41(2): 580–637.
28. Early Goal-Directed Therapy Collaborative Group of Zhejiang Province. The effect of early goal-directed therapy on treatment of critical patients with severe sepsis/septic shock: a multi-center, prospective, randomized, controlled study [inChinese]. Chin Crit Care Med 2010; 6(22): 331–334.
29. Park SK, Shin SR, Hur M, et al. The effect of early goaldirectedtherapy for treatment of severe sepsis or septic shock: a systemic review and meta-analysis. J Crit Care 2017; 38:115–122.
30. Marik PE. Survivng sepsis: online letter to the editor. Crit Care Med 2013; 41(10): 292–293.
31. ProCESS Investigators; Yealy DM, Kellum JA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370(18): 1683–1693.
32. Stevenson EK, Rubenstein AR, Radin GT, et al. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med 2014; 42(3): 625–631.

33. Gotts JE , Matthay MA . Sepsis: pathophysiology and clinical management B MJ 2016; 353: i1585.
34. Cohen J . The immunopathogenesis of sepsis . Nature 2002 ; 420 : 885 – 91 .
35. Tracey KJ , Beutler B , Lowry SF et al. Shock and tissue injury induced by recombinant human cachectin . Science 1986 ; 234 : 470 – 4 .
36. Gerald Diaz, Board Certified Internal Medicine Hospitalist, GrepMed Editor in Chief
37. Vincent, JL. How I treat septic shock. *Intensive Care Med* **44**, 2242–2244 (2018). https://doi.org/10.1007/s00134-018-5401-8

Chapter 5

PURPURA FULMINANS: A HEMORRHAGIC INFARCTION

Dr. Titlee Majumder

email: titleem@svu.ac.in

Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal-700121, India

&

Mr. Arghya Naskar

Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal-700121, India

5. Introduction: Purpura fulminans as a bleeding disorder…

Purpura fulminans is a disorder where your skin bleeds and dies rapidly (skin necrosis). The bleeding is caused by blood clots in the dermal layer (skin layer under the top layer or epidermis). The blood vessels in your skin also collapse and the proteins that cause your blood to clot become overactive. This is called disseminated intravascular coagulation (DIC) (1).DIC causes your body to create too many blood clots, followed by periods of bleeding. This clotting and bleeding can interfere with blood vessels bringing oxygen to your tissues. If your tissues and organs can't get enough oxygen, they will shut down. It is a progressive disorder with intravascular coagulation and circulatory collapse. No such age barrier is obtained in the growth and prognosis of the disorder in terms of age, neonates, children and adults all may face the disease at in terms of acute and chronic stage (2). The disease has been classified into three forms, the first form of purpura is neonatal purpura, which is genetic and chronic as well, people suffering from the hereditary neonatal purpura lack of some anti-coagulant factors like "S,C"& antithrombin III.



Figure1: Idiopathic Purpura (7)

The other moderate form of purpura is idiopathic purpura which is not so common or rather said as post infectious auto-immune disorders. The third most common set of Purpura occurs amongst the severe septic patients where micro-vascular thrombosis is very common (3).

The disease has been first described in eighteenth century was relatively poor to be identified and the microbial strain likely *Meningococcus* and *Streptococcus pneumonia* were reasons of triggering the disease. Any types of Purpura involve major coagulatory dysfunctions, which may be rare to identify and cure as well (4). Lack of vitamin K or its associated co-factors like factor S and C lead to cause the neonatal purpura in a large scale. The birth dates from zero to seven days the onset of the disease happens with an active arterial and venous thrombosis (5).

Whereas the overall coagulation imbalance shows idiopathic purpura in the population which is said as rarest of all and also leads in down regulation of factor C synthesis pathway additionally factor S synthesis pathway. Acute infectious purpura fulminans is also associated with the protein C deficiency, the following can be also triggered by the microbial endotoxins at early stage minor to major skin rashes get visible upon the skin tone later on the lesions become dominant form haemorrhagic bullae, 10 to 20 percent of the overall population often face this type of purpura. The occurrence of the disorder initiates with erythema later on blue and black spots become exceptionally visible upon the core areas of the skin. Patients with the history of severe infections may experience excess bleeding from the various parts of the body most likely rectum, anus, gum etc (6).

5.1Traditional causes of occurrence

Purpura fulminans is caused by defects in the protein C & S in down regulation of synthetic pathwayalongwith the down regulation of anticoagulant factor synthesis. Identification of the cause of purpura fulminans often depends on the patient's age and circumstances of presentation (8). The age based classifications are already discussed in the part5*.

1. *Congenital protein C deficiency* -
   Congenital (inherited) defects in protein C activity are autosomal dominant and may be partial or severe loss of function. Hundreds of natural mutations of the protein C gene (PROC) have been identified.

2. *Acquired protein C deficiency* –

Acquired protein C deficiency is caused by either depletion of available protein C in plasma or decreased protein C synthesis (caused by administration of vitamin K antagonists, severe liver failure or complications of prematurity).

3. Severe acute sepsis –

Purpura fulminans is a presenting feature of severe acute sepsis, such as Neisseria meningitidis, Streptococcus pneumoniae, Group A and B Streptococci, and less commonly with Haemophilus influenzae, Staphylococcus aureus, or Plasmodium falciparum (malaria) infections, particularly in individuals with asplenia.

4. Combination of sepsis and partial congenital defect –

In some cases, a combination of sepsis and a partial congenital defect in the protein C anticoagulant pathway initiates purpura fulminans. Extensive bleeding occurs at the final stage of the disorder

5.1a) Other causes of Purpura Fulminans:

Microbial infections: Microbes, particularly bacteria, can play a significant role in the development of purpura, especially in the context of conditions like purpura fulminans. One of the notable associations is with a bacterial infection known as meningococcemia, caused by Neisseria meningitides (9). Here's how bacteria can be linked to purpura:

Neisseria Meningitides:

This bacterium is a major cause of meningococcal disease, which includes meningitis and sepsis. In severe cases of meningococcal sepsis, the bacteria can trigger a massive inflammatory response and activation of the coagulation system. The formation of blood clots in small blood vessels can lead to purpura fulminans, a life-threatening condition characterized by widespread skin necrosis and organ failure.The purpura seen in meningococcemia is often a result of disseminated intravascular coagulation (DIC), where the normal blood clotting process becomes dysregulated. This bacterium is a significant reason, with its endotoxins triggering a cascade of events leading to disseminated intravascular coagulation (DIC) and purpura fulminans.

Other than Neisseria Meningitides:

- Besides meningococcus, other bacteria like Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus can also contribute to purpura fulminans. Bacterial endocarditis, an infection of the heart valves, can cause emboli to travel through the bloodstream and lead to small vessel clotting, resulting in skin manifestations. Certain streptococcal and staphylococcal infections, including toxic shock syndrome, can lead to skin rashes and, in severe cases, purpura (10).
- Sepsis: Purpura can be a consequence of sepsis, a systemic inflammatory response to infection. In severe sepsis, the immune system's response can trigger widespread activation of the coagulation system, leading to microvascular clotting and organ dysfunction (11).
- Rocky Mountain spotted fever: This is a tick-borne disease caused by the bacterium Rickettsia rickettsii. It can lead to a characteristic rash, which may include purpura, due to the involvement of blood vessels (12).

DIC (Disseminated Intravascular Coagulation): This condition, often secondary to severe infections, trauma, or certain medical conditions, can lead to widespread activation of clotting factors, contributing to purpura fulminans.

5.2 Mechanism of action (of C protein pathway):



Figure 2: Factor C, S and antithrombin III synthesis and activation pathway leading anticoagulation a pathophysiological overview. (13)

Description:

The protein C pathway is one of the major pathways serving regulation for thrombosis, it also limits inflammatory responses and decrease endothelial apoptosis. The compulsory substituents engaged in this pathway are (a) thrombomodulin, (b) endothelial C protein receptor (EPCR), (c) Protein C and (d) Protein S (14). At first the thrombomodulin binds with the circulatory thrombin and form thrombin-thrombomodulin complex through which the unnecessary blood coagulation process is delayed or restricted. At first the coagulating factors like factor-VIII, factor-V along with factor X and prothrombin factor. Now the cofactor for the vitamin K which is cell surface bound and also said as zymogen which gets activated and ensures release of an anticoagulant serine protease (15). Now these cascades of actions activate the membrane bound thrombomodulin followed by endothelial C protein receptor. The EPCR, further stimulates protein C or factor C in association with factor S in inhibiting the process of coagulation by extensive down regulation of factor VIII and factor V. The free flow of the blood in the circulation is assured by presence of these anti-coagulating factors. This has been initiated by the negatively charged membrane-phospholipids. The deactivation of factor VIII is not only done by protein C but also silent association of factor V, which is similar to the Janus- bind protein, has both pro and anti-coagulating potential drive (16).

On the contrary, the protein C has both anti-apoptotic and anti-inflammatory roles. This also exert a specific functions of cleaving the protease activating factor bound to the membrane after forming a complex with APC and EPCR (17). Even the anti-thrombin III which activates the heparin the natural anticoagulant of the circulation fails to activate factors like X, IX, XI, XII so as the process of coagulation can be inhibited. Unnecessary coagulation can be breath taking too some extent, so the process has to be restricted with the reciprocal mechanisms. This reciprocal mechanism has the ability to maintain physiological homeostasis (18). Even the protein expressions on the vascular membranes measured to be equivocal importance in the process of anticoagulation. Genetic mutations, microbial interference and lack of surface protein expressions may increase the tendencies of

anticoagulation in many folds for an individual (19). These major and minor causes of mechanism highlight the multifactorial nature of purpura fulminans, involving both infectious and non-infectious factors

5.3 Disease Associated to Purpura Fulminans:

There are many symptoms are associated along with the disorder Purpura fulminans, which described underneath (20):

1. *Inherited Coagulation Disorders*: Conditions such as protein C deficiency, protein S deficiency, antithrombin III deficiency, and factor V Leiden mutation may predispose individuals to purpura fulminans.

2. *Acquired Coagulation Disorders*: Conditions like autoimmune disorders, certain medications, or liver disease can disrupt the normal coagulation cascade, contributing to the development of purpura fulminans.

3. *Different order of viral Infections*: While less common, certain viral infections, such as varicella-zoster virus and adenovirus, have been associated with purpura fulminans.

4. *Idiopathic symptoms (Unknown Causes):* In some cases, the exact cause remains unidentified, and the condition is considered idiopathic purpura fulminans.

5.4 Classifications: Acquired and Chronic:

Though the basic classifications have already discussed in the introductionof the chapter referring the kinds like (a) idiopathic purpura fulminans, (b) neonatal pupura fulminans and (c)Acute pupura fulminans, here it come to the advance classifications of the disorder based upon its severity. "Purpura fulminans" refers to a severe, rapidly progressing form of purpura, which is a condition characterized by the presence of purple or red discolorations on the skin. This discoloration is caused by bleeding underneath the skin due to the leakage of blood from small vessels. There are two main types of purpura fulminans: chronic and acquired (21).

1. Acquired Purpura Fulminans:

The condition is characterized by widespread blood clotting within small blood vessels, leading to skin necrosis and organ failure (21).

- Conditions such as meningococcemia, which is an infection with the bacteria Neisseria meningitidis, are commonly associated with acquired purpura fulminans.
- Acquired purpura fulminans is more commonly seen in adults than in children.
- The infection triggers an overwhelming inflammatory response and activation of the coagulation system, leading to widespread clotting in small blood vessels.



Figure 3: Acquired Purpura Fulminans (22)

2. Chronic Purpura Fulminans:

This term is sometimes used to describe a rare, chronic condition known as "hereditary purpura fulminans" or "congenital purpura fulminans." (23)

- It is a genetic disorder typically presenting in infancy or early childhood.
- The condition is characterized by a deficiency or dysfunction of proteins involved in the coagulation system, particularly proteins C and S.
- Chronic purpura fulminans can result in severe skin necrosis and widespread thrombosis.



Figure 4: Hemorrhagic bullae in chronic Purpura Fulminans (24)

5.5 Diagnosis, prevention and therapies

5.5a) Prenatal diagnosis of severe protein C or S deficiency:

If the causative mutation of protein C or S deficiency within a family is known, prenatal diagnosis is available for women at risk of having a child with homozygous deficiency. This requires chorionic villous sampling that is associated with a 1% risk of fetal loss. Despite the identification of almost 200 unique mutations in the protein C gene and 131 in the protein S gene,6, 36, 37 the underlying defect is not always identified (25).

Fetal blood sampling offers an alternative method; however, treatment of neonatal purpura fulminans Management of DIC should be based on the clinical and associated laboratory findings. The platelet count should be maintained >50,000 × 109/L and the fibrinogen level >1 g/L. If the etiology is secondary to severe infection, appropriate intravenous antibiotics should be administered (26).

5.5b) Treatment of neonatal purpura fulminans:

If the infant has the classical signs of purpura fulminans, blood samples of the infant and parents should be drawn into citrated tubes for antigen and activity levels of protein C and protein S, before replacement therapy is commenced. There is no protein S concentrate available. FFP/FP (10–20 mL/kg every 12 h) or cryoprecipitate is used as replacement therapy.5 The mainstay of management of severe acquired, transient deficiencies of protein C or S is aggressive treatment of the underlying (27).

- **Initial therapy:**

Anticoagulation therapy should be initiated with administration of protein C replacement therapy (protein C concentrate or FFP/FP) and is an effective long term secondary prophylaxis. Initial anticoagulation consists of either unfractionated heparin (UFH) or low molecular weight heparin (LMWH). UFH should be administered at a dose of 28 U/kg/h with a target anti-Xa level of 0.3–0.7 U/mL. The recommended dose of LMWH is 1.0–1.5 mg/kg/dose every 12 h with a therapeutic target anti-Xa level of 0.5–1 (26).

- **Monitoring of therapy:**

  The therapeutic target activity levels for monitoring of protein C replacement therapy as well as anticoagulation therapy are mentioned above. Due to the risk of bleeding or recurrent purpura fulminans, INRs often need to be monitored on a weekly basis. Point-of-care testing for INR enables such patients to be monitored at home (28).



Figure 5: Treatment algorithm of Purpura Fulminans (Adams and Hobar) (29)

Early purpura fulminans lesions look like traumatic skin bleeds or purpuric rashes, such as immune thrombocytopenic purpura or thrombotic thrombocytopenic purpura; however, purpura fulminans will rapidly progress to necrosis whereas other purpuric rashes do not. In most cases, differential diagnoses may be distinguished from purpura fulminans by other clinical and laboratory findings.

The initial appearance of purpura fulminans lesions is of well-demarcated erythematous lesions which progress rapidly to develop irregular central areas of blue-black haemorrhagic necrosis. Advancing areas of necrosis are often surrounded by a thin border of erythaema that fades into adjacent unaffected skin. Haemorrhage into the necrotic skin causes purpura fulminans lesions to become painful, dark, and raised, sometimes with vesicle or blister (bulla) formation (30). The distribution of purpura fulminans lesions may be different according to the underlying pathogenesis. Purpura fulminans in severe sepsis typically develops in the distal extremities and progresses proximally or appears as a generalised or diffuse rash affecting the whole-body surface. In cases of severe inheritable protein C deficiency, purpura fulminans with disseminated intravascular coagulation manifests within a few hours or days after birth (31).

5.5c) Differential diagnosis:

1. **Calciphylaxis-** it is a rare serious disease where the calcium accumulates within tiny blood vessels of the skin as well as lipid layer. It has been often said as skin ulcers, these are basically blood clots upon the skin and very painful and sometimes major eruptions leads to cause to death (32).

   Symptoms

   a. Deep sores, crust like structures black and brown in colour, fails to heal.
   b. Noticeable purplish net like patterns observed from the skin.
   c. If the place is infected then no such therapies work to heal

2. **Coumadin necrosis-** it is a kind of skin necrosis which is rare & unpredictable. It has high mortality and morbidity rate. The lesions on the skin include an orange peel like appearance initially later on establishes large purplish haemorrhagic spots. Lastly the dry and dark scars have been observed known as necrotic scars and can be only removed by surgery. The other name of this is called warfarin-induced skin necrosis (WISN) (33).

   Symptoms

   a. Noticeable painful lesions, with sudden observed fluid filled blisters
   b. Sensation of paresthesia.
   c. Women having warfarin therapies and in middle age grasps bloody scars in the body.
   d. People in obesity also face the WISN at different phases of body.

3. **Meningococcemia**- it's a microbial disorder often caused by *Neisseria meningitides. Respiratory droplets of an affected person* pass on to the others through sneeze or cough. In most of the cases the upper respiratory tract gets affected. Seasons like winter and spring are the most abundant one for the spreading of this disease. Symptoms of this disease are very common (34).

   Symptoms

   a. Extreme muscle pain along with fever, nausea, agitation, headache.
   b. Rashes with very small red spots (especially on legs)

c. Increasing tendencies of unconsciousness.
d. Bleeding occurs under the skin throughout the larger areas.

4. **Necrotizing fasciitis-** it is basically a kind of soft tissue infection. Streptococcus strain shows this type infection, whereas, streptococcus often called "flesh eating bacteria". In cases of healthy individual this infection is very rare but a small lesion may get affected by this bacterium and later on progressed dominantly (35).

   Symptoms

   a. Initially the skin becomes warm and red.
   b. Then painful red bumps occur and get worsen
   c. Flu can occur, the red bumps later on black dots and lesions can occur.

5. **Thrombotic thrombocytopenic purpura-** It is a very rare life threatening disorder**.** At every small blood vessels blood coagulation occurs throughout the body. The major organs of the body face resistance in flowing of the sufficient amount of blood. Successive bleeding occurs from the major organs like kidneys. Even the platelet counts become rationale low so the topical coagulation also gets hampered (36).

   Symptoms

   a. Fever stands as initial symptoms, later on jaundice or paleness in the skin occurs.
   b. Extreme fatigue, noticeably lower amount of urine
   c. Nausea, headache, vomiting an adverse cases stroke and coma may also occur
   d. Flat red spots can be observed.

6. **Toxic shock syndrome –** the bacterial strain namely Staphylococcus aureus cause such disorder, which is life threatening. The clinical conditions arise to a person by the toxin released from the group A staphylococcus bacteria. The infections can spread men, women and children. Even post-menopausal women are not risk free. Devices such as menstrual cups and sponges can cause infections to the genital part (37).

   Symptoms

   a. sudden high fever, vomiting and diarrhoea occur
   b. muscle fatigue, memory loss, confusion
   c. Seizures and headache, low blood pressures can occur

7. **Thrombophlebitis-** formation of thrombus in vein can cause swelling and inflammation. It is often called deep vein thrombosis by lowering the rate of blood flow. Multiple reasons are found in terms of this disease some are genetic and some are non-genetic. The symptoms include: swelling of the affected part, redness and pain also observed on those parts of the body. The affected place gets warm and tender as well (36).

8. **Vasculitis**- inflammation of the blood vessels is easy works called as vasculties, narrowing of the inner channel of the blood vessels occurs due to thickening of the wall due to inflammation cause vasculities. The disease may cause harm into just one organ or in multiple organs, it can be short term or too some extent long term. Symptoms are more or less similar with the other associated diagnosis of the purpura fulminans, like headache, body-ache, fatigue, low blood pressure and weight loss etc. (37).

5.5 d) Prevention:

For people who have severe congenital protein C deficiency, protein C replacement therapies are available, which is indicated and approved for use in the United States and Europe for the prevention of purpura fulminans. Protein C replacement is often in combination with anticoagulation therapy of injectable low molecular weight heparin or oral warfarin. Before initiating warfarin therapy, a few days of therapeutic heparin may be administered to prevent warfarin necrosis and other progressive or recurrent thrombotic complications. There are vivid reasons of purpura fulminans, so it is difficult to identify the reasons of prognosis of purpura so the prevention of it is also difficult to make. Still some basic remedies have been made to prevent.

1. Protection of skin from damage: The primary protection must be taken from the extreme sunrays, as exposure to sun and its UV rays leads to skin issues. People must be aware of lesion minor or major through which the infections can grow. Usage of same utensils to be prevented strictly (38).

2. Implementation of novel therapeutics: The drug discovery has identified a kind of anti-coagulator drug induced by human plasma having trace amount of heparin the natural

circulatory anti coagulator in it, which reduce the active coagulation process by reducing the number of floating thrombocytes in the circulation. The agent has been named as ceprotin, a potential agent reducing the tendencies of blood coagulation. Whereas many clinical trials has been successfully done in the US population but no such clinical justification in cases of the Asian population has been received. On the other hand, during the process of trial various modes of allergetic reactions, hypersensitivity along with receptor mediated heparin –induced thrombocytopenia has been observed (39).

3. Dietary management: It has been observed that involvement of vitamin K is beneficial for synthesising protein C, which is the major anti-coagulators and the key component in lowering the tendencies of purpura fulminans. Intake of vitamin K rich food for example: broccoli, spinach, cabbage, kale etc. in terms of identifications of Vitamin K deficiency may lead to prevent the disorder (40).

4. Administration of Heparin or drugs of its resemblance: Numerous studies have evidenced that the administration of heparin of heparin like substances lower the chances of down regulation of protein C and S synthetic pathway. The levels of factor X and antithrombin III can be also altered and henceforth said to be as a game changer of the mechanism (41).

5. Alteration of hematologic factors and their concentrations: The factors responsible for the blood coagulation are fibrinogen, tissue thrombo-plastin, factor X, V, VII, XII etc. can be regulated and altered by numerous hematologic therapies. These therapies have clinical importance and also some adverse effects. Especially patients with low concentrations of plasma sodium and potassium levels, patients with acute or chronic renal issues may raise fatal effects due to unknown administration of therapies.

6. Implementation of vasodilators: Topical vasodilators are extremely potential in ensuring free flow of blood. Sometimes due to vascular restrictions the free flow of blood gets hampered so as the cellular depositions initiated in the places of restriction and the indirect trigger of mechanism of coagulation initiated. The substance called nitro-glycerine can be one of the very potential topical vasodilator (42).

5.5 e) Some major complications of these preventive measures:

- The amount of fresh frozen plasma required to reverse disseminated intravascular coagulation associated with purpura fulminans may lead to complications of fluid overload and death, especially in neonates, such as transfusion-related acute lung

injury. Exposure to multiple plasma donors over time increases the cumulative risk for transfusion-associated viral infection and allergic reaction to donor proteins found in fresh frozen plasma.

- Allergic reactions and alloantibody formation are also potential complications, as with any protein replacement therapy.
- Concomitant warfarin therapy in subjects with congenital protein C deficiency is associated with an increased risk of warfarin skin necrosis (43).

5.6) Management of Purpura Fulminans:

In cases of neonatal Purpura Fulminans (44):

I. Immediate treatment with platelet concentrates.
II. Chromogenic assay to assess endogenous activity of protein C, protein S, and antithrombin III (ATIII).
III. If purpura fulminans appears to be due to protein C deficiency, fresh frozen plasma (FFP) transfusion (FFP can later be replaced with low-molecular-weight heparin [LMWH])
IV. Oral anticoagulation with warfarin.
V. Debridement of dead tissue.
VI. If a defect in protein C or ATIII genes is identified, administration of protein C or ATIII concentrates.

In cases of idiopathic Purpura Fulminans (45):

I. Immediate heparinization and infusion of FFP
II. In the setting of acute infection, early, aggressive surgical debridement is warranted; in the absence of infection, a conservative approach is preferred, allowing demarcation of gangrenous areas prior to surgical excision.
III. If compartment syndrome is suspected in patients with tense limbs and distal ischemia, early fasciotomy.
IV. If established gangrene is present, conservative amputation.
V. In cases of severe genetic protein C deficiency, administration of activated protein C (APC).
VI. In some cases, complicated by major vessel thrombosis, administration of tissue plasminogen activator (tPA).

In cases of acute infectious Purpura fulminans (45):

I. Empiric, broad-spectrum intravenous antibiotic therapy against Neisseria meningitidis, streptococci, and methicillin-resistant Staphylococcus aureus (MRSA).
II. Early administration of APC concentrates.
III. Intravenous immunoglobulin (IVIg) therapy.

References

1. Darmstadt GL. Acute infectious purpura fulminans: pathogenesis and medical management. Pediatr Dermatol. 1998;15(3):169–83.

2. Pitukweerakul, S., Sinyagovskiy, P. & Aung, P.P. Purpura Fulminans in Acute Meningococcemia. *J GEN INTERN MED* **32**, 848–849 (2017). https://doi.org/10.1007/s11606-017-4017-y

3. Chalmers, E., Cooper, P., Forman, K., Grimley, C., Khair, K., Minford, A., ... & Mumford, A. D. (2011). Purpura fulminans: recognition, diagnosis and management. *Archives of Disease in Childhood*, *96*(11), 1066-1071.

4. Darmstadt, G. L. (1998). Acute infectious purpura fulminans: pathogenesis and medical management. *Pediatric dermatology*, *15*(3), 169-183.

5. Nolan, J., & Sinclair, R. (2001). Review of management of purpura fulminans and two case reports. *British Journal of Anaesthesia*, *86*(4), 581-586.

6. Spicer, T. E., & Rau, J. M. (1976). Purpura fulminans. *The American Journal of Medicine*, *61*(4), 566-571.

7. Chegondi M, Torres A (2018) Purpura Fulminans and Refractory Shock in a Child. Clin Med Img Lib 4:112. doi.org/10.23937/2474-3682/1510112

8. Warner, P. M., Kagan, R. J., Yakuboff, K. P., Kemalyan, N., Palmieri, T. L., Greenhalgh, D. G., ... & Warden, G. D. (2003). Current management of purpura fulminans: a multicenter study. *The Journal of burn care & rehabilitation*, *24*(3), 119-126.

9. Contou, D., Sonneville, R., Canoui-Poitrine, F., Colin, G., Coudroy, R., Pène, F., ... & De Prost, N. (2018). Clinical spectrum and short-term outcome of adult patients with purpura

fulminans: a French multicenter retrospective cohort study. *Intensive Care Medicine*, *44*, 1502-1511.

10. Hjort, P. F., Rapaport, S. I., & Jørgensen, L. (1964). Purpura Fulminans: Report of a case successfully treated with heparin and hydrocortisone Review of 50 cases from the literature. *Scandinavian journal of haematology*, *1*(3), 169-192.

11. Gürgey, A., Aytac, S., Kanra, G., Secmeer, G., Ceyhan, M., & Altay, C. (2005). Outcome in children with purpura fulminans: report on 16 patients. *American journal of hematology*, *80*(1), 20-25.

12. Dreyfus, M., Magny, J. F., Bridey, F., Schwarz, H. P., Planché, C., Dehan, M., & Tchernia, G. (1991). Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. *New England Journal of Medicine*, *325*(22), 1565-1568.

13. Inamadar Arun C, Palit Aparna,Chapter 11; "Pediatric Dermatology", Purpura Fulminans in Children: An Update; https://doi.org/10.5005/jp/books/11214_11 , 10.5005/jp/books/11214_11 2011, Jaypee Brothers Medical Publishers (P) Ltd.

14. Lécuyer, H., Borgel, D., Nassif, X., & Coureuil, M. (2017). Pathogenesis of meningococcal purpura fulminans. *Pathogens and disease*, *75*(3), ftx027.

15. Lerolle, N., Carlotti, A., Melican, K., Aubey, F., Pierrot, M., Diehl, J. L., & Borgel, D. (2013). Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans. *American journal of respiratory and critical care medicine*, *188*(6), 684-692.

16. Branson, H. E., & Katz, J. (1983). A structured approach to the management of purpura fulminans. *Journal of the National Medical Association*, *75*(8), 821.

17. Campanelli, A., Kaya, G., Ozsahin, A. H., La Scala, G., Jacquier, C., Stauffer, M., ... & Saurat, J. H. (2004). Purpura fulminans in a child as a complication of chickenpox infection. *Dermatology*, *208*(3), 262-264.

18. Khan, I. A., Karmakar, S., Chakraborty, U., Sil, A., & Chandra, A. (2021). Purpura fulminans as the presenting manifestation of COVID-19. *Postgraduate Medical Journal*, *97*(1149), 473-473.

19. Van Der Horst, R. L. (1962). Purpura fulminans in a newborn baby. *Archives of Disease in Childhood*, *37*(194), 436.

20. FRÖDIN, H. (1947). Purpura fulminans and its relation to scarlatina. *Acta Pædiatrica*, *34*(3), 217-233.

21. Brown, D. L., Greenhalgh, D. G., & Warden, G. D. (1998). Purpura fulminans: a disease best managed in a burn center. *The Journal of burn care & rehabilitation*, *19*(2), 119-123.

22. Esmon CT. The protein C pathway. Chest. 2003 Sep;124(3 Suppl):26S-32S. doi: 10.1378/chest.124.3_suppl.26s. PMID: 12970121.

23. Cohen, J. R., Lackner, R., Keller, A., & Douglas, B. (1990). The surgical implications of purpura fulminans. *Annals of vascular surgery*, *4*(3), 276-279.

24. Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet. 1997;350(9091):1590–3.

25. Faust, S. N., & Nadel, S. (2009). Purpura fulminans. *Life-threatening dermatoses and emergencies in dermatology*, 45-55.

26. Fourrier, F., Lestavel, P., Chopin, C., Marey, A., Goudemand, J., Rime, A., & Mangalaboyi, J. (1990). Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. *Intensive care medicine*, *16*, 121-124.

27. MORSE, T. S., ROWE, M. I., & HARTIGAN, M. (1966). Purpura fulminans. *Archives of Surgery*, *93*(2), 268-270.

28. SILBART, S., & Oppenheim, W. (1985). Purpura fulminans: medical, surgical, and rehabilitative considerations. *Clinical Orthopaedics and Related Research (1976-2007)*, *193*, 206-213.

29. Meningococcal septicaemia complications involving skin and underlying deeper tissues – management considerations and outcome - Scientific Figure on ResearchGate. Available from: https://www.researchgate.net/figure/Treatment-algorithm-for-purpura-fulminans-adapted-from-Adams-and-Hobar-3_fig2_5777962 [accessed 29 May, 2024]

30. Powars, D., Larsen, R., Johnson, J., Hulbert, T., Sun, T., Patch, M. J., ... & Chan, L. (1993). Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. *Clinical infectious diseases*, *17*(2), 254-261.

31. Childers, B. J., & Cobanov, B. (2003). Acute infectious purpura fulminans: a 15-year retrospective review of 28 consecutive cases. *The American Surgeon*, *69*(1), 86-90.

32. Marlar, R. A., & Neumann, A. (1990, October). Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. In *Seminars in thrombosis and hemostasis* (Vol. 16, No. 04, pp. 299-309). Copyright© 1990 by Thieme Medical Publishers, Inc.

33. Rivard, G. E., David, M., Farrell, C., & Schwarz, H. P. (1995). Treatment of purpura fulminans in meningococcemia with protein C concentrate. *The Journal of pediatrics*, *126*(4), 646-652.

34. Ward, K. M., Celebi, J. T., Gmyrek, R., & Grossman, M. E. (2002). Acute infectious purpura fulminans associated with asplenism or hyposplenism. *Journal of the American Academy of Dermatology*, *47*(4), 493-496.

35. Contou, D., Urbina, T., & de Prost, N. (2022). Understanding purpura fulminans in adult patients. *Intensive care medicine*, *48*(1), 106-110.

36. Hassan, Z., Mullins, R. F., Friedman, B. C., Shaver, J. R., Alam, B., & Mian, M. A. (2008). Purpura fulminans: a case series managed at a regional burn center. *Journal of burn care & research*, *29*(2), 411-415.

37. Theron, A., Dautremay, O., Boissier, E., Zerroukhi, A., Baleine, J., Moulis, L., ... & Biron-Andreani, C. (2022). Idiopathic purpura fulminans associated with anti-protein S antibodies in children: a multicenter case series and systematic review. *Blood Advances*, *6*(2), 495-502.

38. Branson, H., Marble, R., Katz, J., & Griffin, J. (1983). Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. *The Lancet*, *322*(8360), 1165-1168.

39. GERSON, W. T., DICKERMAN, J. D., BOVILL, E. G., & GOLDEN, E. (1993). Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. *Pediatrics*, *91*(2), 418-422.

40. Madden, R. M., Gill, J. C., & Marlar, R. A. (1990). Protein C and protein S levels in two patients with acquired purpura fulminans. *British journal of haematology*, *75*(1), 112-117.

41. Patterson, J. H., Pierce, R. B., Amerson, J. R., & Watkins, W. L. (1965). Dextran therapy of purpura fulminans. *New England Journal of Medicine*, *273*(14), 734-737.

42. Koller, F. V., Gasser, C., Krüsi, G., & De Muralt, G. (1950). Purpura fulminans nach Scharlach mit Faktor V-Mangel und Antithrombinüberschuß. *Acta Haematologica*, *4*(1), 33-55

43. Leclerc, F., Leteurtre, S., Noizet, O., Sadik, A., & Cremer, R. (2003). Purpura fulminans de l'enfant. In *Conférence d'actualisation* (pp. 615-630).

44. Kumagai, K., Nishiwaki, K., Sato, K., Kitamura, H., Yano, K., Komatsu, T., & Shimada, Y. (2001). Perioperative management of a patient with purpura fulminans syndrome due to protein C deficiency. *Canadian Journal of Anesthesia*, *48*(11), 1070-1074.

45. Besner, G. E., & Klamar, J. E. (1998). Integra artificial skin as a useful adjunct in the treatment of purpura fulminans. *The Journal of burn care & rehabilitation*, *19*(4), 324-329.